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Astaxanthin (3,3′-dihydroxy-β, β′-carotene-4,4′-dione) is a liposoluble carotenoid 
usually ingested through the supplementation of Haematococcus pluvialis-derived 
antioxidant products. Based upon research conducted in mice, astaxanthin 
supplementation can improve indices of exercise recovery, metabolism and 
performance due to its potent antioxidant capacity. In exercising humans, similar 
observations have yet to be consistently realised. The following investigations were 
conducted to further explore the effect of astaxanthin supplementation on exercise 
recovery, substrate utilisation and endurance performance in recreationally active and 
trained human males. As a potent antioxidant compound, astaxanthin is suggested to 
provide a recovery benefit through the inhibition of pro-oxidant and pro-inflammatory 
intermediates post-exercise. This ability was investigated in Study 1 using a 30 min 
downhill run to induce muscle damage. In comparison to the placebo, indices of 
muscle damage and recovery post-exercise were not influenced by the prior eight-
week intake of astaxanthin. Additionally, the lipophilic properties of astaxanthin allow 
it to protect and upregulate key metabolic enzymes involved in fat oxidation. Study 2 
therefore utilised a graded exercise protocol to investigate whether four or eight weeks 
of astaxanthin supplementation could enhance the fat oxidative capacity during 
exercise. Again, no differences were reported when compared to the placebo. 
Astaxanthin has, however, been reported to peak in human plasma within the first 
week of intake. Study 3 was therefore the first to investigate and report an ergogenic 
and metabolic effect of astaxanthin following a shorter seven-day supplementation 
period, with improvements in performance and whole-body fat oxidation reported 
during a 40 km cycling time trial. Collectively, these studies highlight the importance 
of developing an optimal dosing strategy for astaxanthin intake based upon human 
pharmacokinetic data. With this knowledge, further explorations into the efficacy of 
astaxanthin in exercising humans can be made while using a supplementation strategy 
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Reactive oxygen and nitrogen species (RONS) produced during exercise are 
recognised as fundamental stressors that can promote improvements in athletic 
performance and overall health (Busso, 2003, Radak et al., 2013, 2017). To ensure 
that improvements are sustained, recreationally active and trained individuals are 
required to manipulate the volume, intensity and frequency of each exercise bout over 
time (Busso, 2003). During periods of intense exercise training and competition, a 
system of interrelated endogenous antioxidant compounds (i.e. superoxide dismutase, 
catalase, glutathione peroxidase) work together to ensure RONS production does not 
become detrimental (Powers and Jackson, 2008). Multifaceted in its function, this 
system can prevent and delay the oxidation of biomolecules through removing, 
deactivating and preventing the formation of RONS (Bast and Haenen, 2015, Wagner, 
2015). 
If exercise becomes too vigorous, however, an excessive production of RONS can 
overwhelm the endogenous antioxidant defence system, causing a state of oxidative 
stress (Pingitore et al., 2015). Consequently, lipid, protein and nucleic molecules may 
become damaged, with potentially detrimental impacts on normal physiological 
function (Dalle-Donne et al., 2006, Peternelj and Coombes, 2011). The 
intake/ingestion of exogenous antioxidants has, therefore, become common practice 
in both recreationally active and trained populations (Peternelj and Coombes, 2011). 
As essential non-enzymatic molecules, exogenous antioxidants have the potential to 
supplement the endogenous antioxidant defence system if adequately sourced from 




can be sourced through either dietary intake or supplementation is the xanthophyll 
carotenoid, astaxanthin. Previously, astaxanthin has been suggested to enhance indices 
of exercise recovery, metabolism and performance as a result of its potent antioxidant 
capacity (Aoi et al., 2003, 2008, 2018, Ikeuchi et al., 2006, Earnest et al., 2011, Liu et 
al., 2014). Evidence to support this notion has been predominantly derived from 
studies using in vitro and in vivo animal models (Aoi et al., 2003, 2008, 2018, Ikeuchi 
et al., 2006, Liu et al., 2014), with similar observations in exercising humans yet to be 
consistently realised (Bloomer et al., 2005, Earnest et al., 2011, Djordjevic et al., 2012, 
Res et al., 2013, Baralic et al., 2015). The following chapter is written to 1) introduce 
the field of antioxidants and oxidative stress, and 2) critically appraise the current 
literature surrounding astaxanthin and its potential application as a dietary supplement 
within exercising humans. Underlying mechanistic factors pertaining to exercise 
recovery, metabolism and performance will also be considered alongside the 
identification of present and future areas of research focus. 
 
1.2. Major Reactive Species 
First detected in a biological system in 1954 (Commoner, Townsend and Pake, 1954), 
the term “free radical” is used to define an atom or a group of atoms that contain one 
or more unpaired electrons (Halliwell and Gutteridge, 2007). This imbalance in atom 
electron content often results in the production of a highly reactive and unstable 
molecule. As a collective, these reactive species are known as reactive oxygen or 




further categorised into either reactive oxygen species (ROS) or reactive nitrogen 
species (RNS). 
The most abundant ROS is formed when oxygen is incompletely reduced, a 
biochemical reaction that yields the superoxide anion radical (Kerksick and Zuhl, 
2015). Considered as relatively membrane impermeable, superoxide exhibits a 
moderately long half-life of ~ 5 s at a physiological pH (Marklund, 1976, Jaeschke, 
2010) which enables it to diffuse and subsequently react with a number of intracellular 
targets (Powers et al., 2011). Despite this, superoxide is considered somewhat 
unreactive in comparison to other reactive species (Halliwell and Gutteridge, 2007). 
It does, however, possess an ability to react and produce a series of downstream 
derivatives, such as singlet oxygen, hydrogen peroxide (H2O2), hydroxyl radical 
intermediates and peroxynitrite, respectively (Reid, 2016a). 
Singlet oxygen is a non-radical ROS since no electrons are unpaired and is formed 
during the dismutation of superoxide in water, or as a by-product of the reaction 
between peroxyl radical intermediates (Halliwell and Gutteridge, 2007, Powers et al., 
2011). Although non-radical, the membrane permeability and no spin restriction of 
singlet oxygen allow it to possess a relatively high oxidising potential in vivo 
(Halliwell and Gutteridge, 2007, Powers and Jackson, 2008). Hydrogen peroxide is 
also a non-radical ROS, formed during the dismutation of superoxide by the 
superoxide dismutase enzymes (Halliwell and Gutteridge, 2007). Although H2O2 
cannot oxidise lipid or nucleic biomolecules directly, it can diffuse within the cell as 
well as across the membrane, inactivating some enzymes, while also possessing 




controlling cell proliferation and apoptosis) (Halliwell, Clement and Long, 2000, 
Powers and Jackson, 2008). Hydrogen peroxide can also be reduced further, forming 
the more potent and highly reactive hydroxyl radical intermediate (Kerksick and Zuhl, 
2015). Although non-membrane permeable (Powers et al., 2011), the hydroxyl radical 
possesses a strong oxidising potential, making it capable of damaging protein, lipid 
and nucleic biomolecules (Dalle-Donne et al., 2006, Lipinski, 2011). Its high 
reactivity, however, leads to it exhibiting an extremely short half-life of ~ 1 ns in vivo 
(Kehrer and Klotz, 2015). As such, the detection of RONS are often dependent upon 
the measurement of downstream biomarkers most pertinent to the redox reactions 
taking place and/or the resultant damage to macro-molecular targets; including lipid, 
protein and nucleic biomolecules (Uttara et al., 2009, Powers et al., 2011, Margaritelis 
et al., 2016).  
With superoxide considered as the parent molecule of the ROS cascade, nitric oxide 
(NO) is often considered as the parent molecule of the RNS cascade (Reid, 2016b). In 
healthy skeletal muscle, NO is predominantly synthesised via two NO synthases 
(NOS); neuronal NOS (nNOS) and endothelial NOS (eNOS) (Kobzik et al., 1994). A 
third NOS, inducible NOS (iNOS) is thought to not exist at significant levels in healthy 
skeletal muscle (Reid, 2016b), but is predominantly present in many inflammatory 
conditions (Powers and Jackson, 2008). Similar to superoxide, NO is thought to be 
neither highly toxic nor reactive in vivo, with its rapid removal enabled by its diffusion 
through tissues into red blood cells, where it is then converted to nitrate by reaction 
with oxyhaemoglobin (Pacher, Beckman and Liaudet, 2007). Nitric oxide can, 
however, react rapidly with superoxide, producing a more destructive and reactive 




Liaudet, 2007, Powers, Talbert and Adhihetty, 2011). Peroxynitrite is the destructive 
end point of the RNS cascade (Reid, 2016a), with its production reported to damage 
complex I of the electron transport chain (ETC), subsequently disrupting adenosine 
triphosphate synthesis (Riobó et al., 2001). It can also cause the oxidative damage of 
nucleic molecules, the nitration of proteins and the depletion of thiol groups (Powers 
et al., 2011). Paradoxically, it also indirectly alters cellular pathway signalling through 
reducing the bioavailability of both superoxide and NO, respectively (Reid, 2016b). 
 
1.3. Sources of RONS 
There are both exogenous and endogenous sources of RONS. Exogenous sources are 
characterised via an interaction with different environmental stressors; including 
exercise (Peternelj and Coombes, 2011). Understanding the interaction between 
exercise and endogenous RONS production is key when elucidating the potential 
efficacy of antioxidant supplementation. Across the exercising skeletal muscle, 
various sources of RONS exist, including; the mitochondria, sarcoplasmic reticulum, 
transverse tubules, sarcolemma and cytosol, with enzymes such as nicotinamide 
adenine dinucleotide phosphate (NADPH) oxidase, xanthine oxidase (XO), NOS and 
phospholipase A2 (PLA2) also associated (Powers and Jackson, 2008, Powers, Talbert 
and Adhihetty, 2011). 
Originally, complexes I and III of the mitochondrial ETC were thought to be the main 
sources of RONS production within the exercising skeletal muscle (Davies et al., 
1982), with early research quantifying this as 2-5% of total mitochondrial respiration 




however, does not support this estimate, indicating that mitochondrial respiration 
actually contributes a modest 0.15% towards RONS production (St-Pierre et al., 
2002). Higher levels of mitochondrial RONS production are also reported during basal 
respiration when compared to any form of active respiration (Di Meo and Venditti, 
2001). It is therefore clear that additional sources need to be considered, especially 
during exercise. 
The NADPH oxidase enzymes are now considered as predominant sources of 
intracellular RONS production (Sakellariou et al., 2013, Jackson, Vasilaki and 
McArdle, 2016), with XO and NADPH oxidase enzymes also thought to contribute to 
superoxide release into the extracellular space. Localised to the sarcoplasmic 
reticulum, transverse tubules and sarcolemma (Powers et al., 2011, Jackson, Vasilaki 
and McArdle, 2016), NADPH oxidases are released during the depolarisation of 
contracting skeletal muscle. Once released, these enzymes catalyse the transfer of 
electrons from NADPH to molecular oxygen, yielding superoxide (Hidalgo et al., 
2006, Sakellariou et al., 2013). The XO pathway, in comparison, is triggered under 
conditions of intense skeletal muscle contraction, hypoxia or ischemia, whereby XO 
utilises molecular oxygen when converting hypoxanthine into xanthine and uric acid, 
again yielding superoxide (Harris, Sanders and Massey, 1999, Kerksick and Zuhl, 
2015). Although their specific roles during exercise require further elucidation, 
NADPH oxidase activity is reported to be upregulated by endurance exercise (Dong 
et al., 2011), with XO associated with eccentric exercise and the secondary 
inflammatory response (Hellsten et al., 1997). As such, the NADPH oxidase and XO 
enzymes are now considered as key contributors to the whole-body oxidative response 




Additional sources of RONS include the NOS and PLA2 enzymes. In healthy skeletal 
muscle, nNOS and eNOS are considered the two major sources of NO, with iNOS 
associated with many inflammatory conditions (Kobzik et al., 1994, Reid, 2016b). The 
NOS enzymes produce NO continuously during the synthesis of L-arginine (Powers 
and Jackson, 2008), however, this production is increased further during the 
contraction of skeletal muscle (Kobzik et al., 1994). Endothelial NOS is localised to 
the muscle mitochondria (Kobzik et al., 1995, Powers and Jackson, 2008), with the 
NO produced at this site reported to bind to complex IV of the ETC, producing 
superoxide via the oxidation of ubiquinol, an upstream electron carrier (Poderoso et 
al., 1996, Riobó et al., 2001). In comparison, nNOS is localised to the muscle 
sarcolemma, where it is strongly expressed by fast-twitch muscle fibres and appears 
to be the primary source of NO within the skeletal muscle during exercise (Hirschfield 
et al., 2000, Powers et al., 2011). The PLA2 enzymes, in contrast, stimulate 
intracellular RONS production in the mitochondria and cytosol, as well as the release 
of RONS into the extracellular space via lipoxygenase-dependent systems (Powers, 
Nelson and Hudson, 2011). While calcium-independent PLA2 is suggested to be a 
major determinant of RONS activity under basal conditions, calcium-dependent PLA2 
is activated when intracellular calcium levels are elevated, implicating its role in 
RONS production within the contracting skeletal muscle (Powers, Nelson and 





1.4. The Antioxidant Defence System 
Free radicals can become reduced, a redox reaction that involves the gaining of an 
electron from a target molecule causing said molecule to become oxidised (Dröge, 
2002, Slattery, Bentley and Coutts, 2015). Although this process of electron transfer 
can initiate adaptive and regulatory cellular signalling cascades (Powers et al., 2010), 
uncontrolled oxidation of target molecules can become maladaptive, initiating a state 
of oxidative stress (Alessio et al., 2000). As such, there exists a plethora of interrelated 
antioxidant compounds, that in relatively low concentrations, work synergistically to 
prevent or delay the oxidation of biomolecules (Bast and Haenen, 2015). Forming the 
antioxidant defence system, these multifunctional compounds can; donate electrons to 
highly reactive species, reducing them to less active derivatives, prevent less reactive 
molecules from becoming more potent, limit the availability of pro-oxidant materials, 
and even aid in the repair of RONS-induced damage (Powers et al., 2011, Slattery, 
Bentley and Coutts, 2015, Wagner, 2015). 
Superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GPX) and 
glutathione reductase (GR) are often considered as the primary enzymatic endogenous 
antioxidants, with glutathione and uric acid considered as the primary non-enzymatic 
antioxidants (Powers and Jackson, 2008, Peternelj and Coombes, 2011). First 
discovered in 1969 (McCord and Fridovich, 1969), SOD catalyses the dismutation of 
superoxide, yielding the less reactive H2O2 alongside molecular oxygen (Halliwell and 
Gutteridge, 2007). To facilitate this function, SOD associates with transition metals 
such as copper (Cu), zinc (Zn) and manganese (Mn) to form CuZn-SOD and Mn-SOD 




localised to the cytosol and the mitochondrial intermembrane space and is often 
termed SOD1, with CuZn-SOD in the extracellular space often termed SOD3 (Powers 
et al., 2011). In contrast, the Mn-SOD isoform, often termed SOD2, is localised to the 
intracellular compartment, inside the mitochondrial matrix (Kerksick and Zuhl, 2015). 
The ubiquitous enzyme CAT also associates with a transient metal, in this case iron, 
and is responsible for the transformation of H2O2 into water and molecular oxygen 
(Powers et al., 2004). Similar to CAT, GPX is also responsible for the scavenging of 
H2O2 (Holmgren et al., 2005). Localised to the cytosol and mitochondria, GPX holds 
a greater affinity to H2O2 and therefore exerts a greater antioxidant effect (Tsutsui, 
Kinugawa and Matsushima, 2011). Its function, however, is dependent upon 
glutathione, a non-enzymatic antioxidant which recycles oxidised GPX back to a 
reduced/functional state (Powers et al., 2004). Glutathione achieves this through 
donating an electron to GPX, a process which oxidises glutathione, forming 
glutathione disulphide (GSSG). Due to its functional importance, the reduction of 
GSSG back to glutathione is paramount, a process accomplished by the GR enzyme, 
with NADPH acting as the reducing agent (Powers and Jackson, 2008). 
Glutathione, therefore, is a clear example of the intercalation that exists between 
enzymatic and non-enzymatic antioxidant defences. In addition to reducing GPX, 
glutathione can also reduce and recycle pro-oxidant forms of vitamins C and E 
(Halliwell and Gutteridge, 2007, Villanueva and Kross, 2012), as well as reacting 
directly with, and reducing, a number of RONS (Yu, 1994). Another non-enzymatic 
antioxidant that functions as an electron donor is uric acid (Halliwell and Gutteridge, 




associates with iron and copper, and subsequently prevents the production of hydroxyl 
radical intermediates (Halliwell and Gutteridge, 2007, Powers et al., 2011).  
As SOD, CAT and GPX are associated with the mitochondria, it is perhaps 
unsurprising that these enzymes are all prominent within oxidative type I muscle fibres 
(Powers et al. 1994, Powers et al. 2004). Furthermore, endurance exercise is reported 
to upregulate both SOD and GPX activity within the skeletal muscle (Criswell et al., 
1993, Powers et al., 1994), with evidence regarding CAT currently less clear (Powers 
and Jackson, 2008). Glutathione is also reported as being upregulated in skeletal 
muscle fibres following endurance exercise training (Sen et al., 1992, Leeuwenburgh 
et al., 1997, Ohkuwa, Sato and Naoi, 1997). Although this finding is not currently 
replicated consistently for uric acid (Powers et al., 2011), it is accepted that prolonged 
endurance exercise can cause its upregulation, making it plausible that it could exert 
some form of antioxidant function during exercise (Neubauer et al., 2008). 
Evidence therefore suggests that adherence to endurance exercise training provides a 
fundamental stressor, that if controlled, can upregulate many components of the 
endogenous antioxidant defence system. As such, the efficacy of exogenous 
antioxidant supplementation has been debated, with previous research questioning 
whether an overprotection from RONS could attenuate the exercise-induced adaptive 
responses to this fundamental stressor (Gomez-Cabrera et al., 2008, Ristow et al., 
2009). If exercise training becomes too vigorous, however, this same stressor can 
become deleterious, overwhelming the endogenous antioxidant defence system, 
causing a state of oxidative stress (Pingitore et al., 2015). As such, the intake/ingestion 




and trained populations (Peternelj and Coombes, 2011). As essential non-enzymatic 
molecules, exogenous antioxidants have the potential to supplement the endogenous 
antioxidant defence system if adequately sourced from the diet (Slattery, Bentley and 
Coutts, 2015). The following section is written to introduce and critically appraise the 
current literature surrounding a novel and potentially potent antioxidant named 
astaxanthin and its potential application as an exogenous antioxidant supplement 
within exercising humans. Underlying mechanistic factors pertaining to exercise 
recovery, metabolism and performance will also be considered alongside the 
identification of present and future areas of research focus. 
 
1.5. Introduction to Astaxanthin 
Astaxanthin (3,3′-dihydroxy-β, β′-carotene-4,4′-dione) is a naturally occurring 
carotenoid found in marine species, such as microalgae, crustacea, fish and some birds 
(Guerin, Huntley and Olaizola, 2003, Hussein et al., 2006). Utilised in aquaculture, 
astaxanthin provides the characteristic reddish pigment to farm-raised salmon tissue 
(Ambati et al., 2014). Following the initial work of Kurashige et al. (1990) and Miki 
(1991), however, an alternative use for astaxanthin as a potent antioxidant compound 
in both in vitro and in vivo systems has been suggested. As it is oxygenated 
(C40H52O4), astaxanthin is classified as part of the xanthophyll sub-species of the 
carotenoid family (Visioli and Artaria, 2017), with its potency seemingly underpinned 
by its structure at a molecular level (Miki, 1991, Goto et al., 2001, Guerin, Huntley 
and Olaizola, 2003, Hussein et al., 2006). With a molecular mass of 596.84 gmol−1, 




a polyene chain and contain the oxygenated keto and hydroxyl moieties (Visioli and 
Artaria, 2017) (Figure 1.1). The presence of the polyene chain alongside each moiety 
enables astaxanthin to exert multiple antioxidant functions, namely in the scavenging 
and quenching of RONS, both within and at the surface of the phospholipid membrane 
(Miki, 1991, Goto et al., 2001) (Figure 1.2). 
 
 




Figure 1.2 Schematic depicting the ability of astaxanthin, in comparison to other 
popular phytochemicals, to be able to exert its antioxidant function both within and at 




1.6. Sources of Astaxanthin 
As the human organism is unable to synthesise astaxanthin naturally, its uptake is 
dependent upon the dietary intake of foods, such as salmon, lobster, shrimp and crab 
(Visioli and Artaria, 2017). Whilst current data regarding the dietary intake of 
astaxanthin are limited, it is estimated that more than 70% of salmon production 
worldwide is farm-raised where astaxanthin is utilised as a feeding additive (Visioli 
and Artaria, 2017). If it is assumed that all dietary sources of seafood are obtained 
from aquaculture, it is estimated that the average European adult would consume 
between 0.8 and 2.0 mgday−1 astaxanthin, with the higher percentile not expected to 
exceed intakes of 4.1 mgday−1 (EFSA FEEDAP Panel, 2005). Alternatively, the 
intake of astaxanthin is possible through regular dietary supplementation, with a 
typical intake of 4 mgday−1 astaxanthin recommended across several brands of 
commercially produced astaxanthin products (EFSA NDA Panel, 2014). Existing as 
three separate stereoisomers [(3S, 3’S), (3R, 3’R), and (3R, 3’S)] (Shah et al., 2016), 
the commercial applications of astaxanthin range from daily capsules and soft gels to 
energy drinks and powders (Ambati et al., 2014). Although the production of 
astaxanthin for aquacultural purposes can be sourced from a range of synthetic and 
natural sources, the only form currently commissioned for direct human consumption 
as a commercial product is the (3S, 3’S)-isomer (Shah et al., 2016, Visioli and Artaria, 
2017). As a result, recent endeavours have been made to improve the production of 
astaxanthin from natural sources, such as Haematococcus pluvialis, to ensure that 





1.7. Bioavailability of Astaxanthin in Humans 
Upon ingestion, it is assumed that the intestinal absorption of carotenoids, such as 
astaxanthin, are similar to those of dietary lipids (Visioli and Artaria, 2017). 
Carotenoids, for example, associate with lipid micelles in the lumen following 
consumption, a process which allows for passive diffusion into the lining of the 
intestinal mucosa. Following this, carotenoids then associate with chylomicrons and 
are subsequently released into the lymphatic system. At the liver, chylomicrons are 
digested by lipoprotein lipase, a process which allows carotenoids to assimilate with 
other lipoproteins, such as low-density lipoproteins, to be subsequently transported to 
other tissues in the body; including both adipose and muscle tissue (Visioli and 
Artaria, 2017). 
Bioavailability data is available from research that has quantified the uptake and 
elimination kinetics of astaxanthin in human plasma using high-performance liquid 
chromatography (Østerlie, Bjerkeng and Liaaen-Jensen, 2000, Mercke Odeberg et al., 
2003, Coral-Hinostroza et al., 2004, Rüfer et al., 2008). This method of analysis was 
used by Rüfer et al. (2008) during the investigation of 28 healthy males over a 4 week 
period. Prior to study onset, astaxanthin concentrations were quantified as non-
detectable, following which two randomised groups (n = 14 each group) consumed 
either 250 g of wild or aquacultured salmon daily, to obtain ~ 1.25 
mgday−1 astaxanthin (5 µg astaxanthing−1 salmon flesh). Following 6 days of 
consumption, astaxanthin concentrations reached a plateau of 33.7 ± 16.2 
nmolL−1 (wild salmon) and 52.4 ± 16.2 nmolL−1 (aquacultured salmon), respectively. 




(Rüfer et al., 2008). It therefore appears that when the intake of astaxanthin is chronic, 
maximal concentrations can be achieved and maintained within the first week of 
intake, even when astaxanthin is obtained from different sources. This data, however, 
is collated from one study only, where astaxanthin was consumed as part of the diet, 
requiring a daily intake of 250 g salmon (Rüfer et al., 2008). Future research should, 
therefore, aim to clarify the bioavailability of astaxanthin from a variety of different 
sources, including supplementation, with information regarding the elimination 
kinetics also of importance to understand how the availability of astaxanthin may 
diminish in humans over time. 
Currently, the European Food Safety Authority (EFSA) advise an acceptable daily 
intake (ADI) of 0.034 mgkg−1day−1 astaxanthin (2.38 mgday−1 in a 70 kg human) 
(EFSA FEEDAP Panel, 2014, EFSA NDA Panel, 2014). Despite this, 
pharmacokinetic data are available from studies that have issued acute doses of 40 and 
100 mg, respectively (Østerlie, Bjerkeng and Liaaen-Jensen, 2000, Mercke Odeberg 
et al., 2003, Coral-Hinostroza et al., 2004). Following the ingestion of an acute H. 
pluvialis-derived 40 mg capsule, maximal plasma concentrations of 55.2 ± 15.0 µgL−1 
astaxanthin were recorded in eight healthy male participants (Mercke Odeberg et al., 
2003). In the same study, uptake was significantly enhanced if astaxanthin was 
ingested as one of three lipid-based formulations (n = 8 per group), with maximal 
plasma concentrations in the range of 90.1 and 191.5 µgL−1 reported (Mercke 
Odeberg et al., 2003). As a result, it is advised that astaxanthin should be consumed 
alongside the intake of dietary fats to ensure uptake can be optimised (Okada, Ishikura 




mgL−1 and 0.28 ± 0.12 mgL−1 are reported in the plasma following an acute intake 
of 100 mg astaxanthin (Østerlie, Bjerkeng and Liaaen-Jensen, 2000, Coral-Hinostroza 
et al., 2004). Although a high level of variance exists between the two studies, this 
may be explained by the low sample sizes (n = 3 per study), which should be addressed 
in future research (Østerlie, Bjerkeng and Liaaen-Jensen, 2000, Coral-Hinostroza et 
al., 2004). 
Additional information is also available regarding the pharmacokinetics of astaxanthin 
following acute supplementation regimes. Indeed, maximal blood astaxanthin 
concentrations are observed 8-10 h following the intake of 40 mg astaxanthin (n = 32) 
(Mercke Odeberg et al., 2003), with similar times of 6.7 ± 1.2 h (n = 3) and 11.5 h (n = 
3) also observed following doses of 100 mg (Østerlie, Bjerkeng and Liaaen-Jensen, 
2000, Coral-Hinostroza et al., 2004). Furthermore, a half-life of 15.9 ± 5.3 h is 
reported following a 40 mg dose (Mercke Odeberg et al., 2003), with half-lives of 21 
± 11 and 52 ± 40 h reported following the intake of a 100 mg dose (Østerlie, Bjerkeng 
and Liaaen-Jensen, 2000, Coral-Hinostroza et al., 2004). It therefore appears that the 
concentration–time profile of astaxanthin is monophasic following ingestion and can 
be described as a one-compartment model. Future research should seek to replicate 
these findings in doses equivalent to those advocated by the EFSA (0.034 mgkg−1), 
as well as those available in commercial astaxanthin products (4 mg). In doing so, 
optimal dosing strategies may be developed and subsequently implemented for both 





1.8. Mechanism of Action 
In comparison to other popular phytochemicals, astaxanthin has previously been 
reported to possess a significantly greater antioxidant function (Kurashige et al., 1990, 
Miki, 1991, Shimidzu, Goto and Miki, 1996), with its antioxidant activities quantified 
as 10-fold greater than other carotenoids, such as -carotene, and 100-fold greater than 
-tocopherol (vitamin E) (Miki, 1991). In particular, astaxanthin seemingly holds an 
affinity for singlet oxygen and peroxyl radical intermediates (Miki, 1991, Shimidzu, 
Goto and Miki, 1996, Goto et al., 2001, Visioli and Artaria, 2017). Through the 
process of energy transfer, for example, astaxanthin is able to quench singlet oxygen, 
yielding ground state oxygen alongside astaxanthin in a triplet-excited state (Visioli 
and Artaria, 2017). As a carotenoid, astaxanthin is then able to dissipate this energy 
by interacting with surrounding solvent, returning back to the ground state structurally 
intact, ready to participate in further quenching cycles (Stahl and Sies, 2003, Visioli 
and Artaria, 2017). Additionally, astaxanthin is also able to scavenge and deactivate 
peroxyl radical intermediates, a function likely dependent upon the formation of 
resonance stabilised, carbon-centred radical adducts (Stahl and Sies, 2003, Visioli and 
Artaria, 2017). As such, an ability for astaxanthin to extensively protect lipid-rich 
structures against peroxidation during periods of oxidative stress has been suggested 
(Miki, 1991, Palozza and Krinsky, 1992, Naguib, 2000, Goto et al., 2001). 
Research utilising animal models have also identified a potential for astaxanthin to 
indirectly modulate the endogenous antioxidant defence system through interacting 
with redox sensitive transcription factors, such as nuclear factor erythroid 2-related 




Kelch-like ECH-associated protein 1 (Keap1); however, during periods of oxidative 
stress, modifications to cysteine residues on Keap1 cause Nrf2 to be released and 
translocated to the nucleus where it binds to the antioxidant response element (ARE) 
(Kaspar, Niture and Jaiswal, 2009, Done and Traustadóttir, 2016). Once activated, the 
Nrf2–ARE signalling pathway initiates the transcription of several cytoprotective 
genes and enzymes capable of upregulating the endogenous antioxidant response to 
an oxidative stressor, potentially implicating Nrf2 in the beneficial effects of exercise 
(Done and Traustadóttir, 2016). 
Similarly, phytochemicals can also stimulate the activation of the Nrf2–ARE pathway, 
a process which may occur through the modification of different cysteine residues to 
those targeted through exercise, suggesting a potential synergism between exercise 
and phytochemicals in the upregulation of antioxidant defence (Done and 
Traustadóttir, 2016). Although a specific mechanism of action has yet to be elucidated, 
research conducted in animal models report increases in Nrf2 expression, alongside 
the upregulation of endogenous antioxidant enzymes, including SOD, CAT and GPX, 
following astaxanthin administration (Yang et al., 2011, 2014, Xu et al., 2017). As key 
components of the endogenous antioxidant defence system (Powers et al., 2011), it is 
plausible that astaxanthin could activate endogenous antioxidant defence pathways 
upon administration. Future exploratory research should therefore be conducted to 
investigate this mechanism further, including the interaction between astaxanthin and 





1.9. Safety of Astaxanthin Supplementation 
In 2014, the EFSA Panel on Additives and Products or Substances used in Animal 
Feed (FEEDAP) advocated an ADI of 0.034 mgkg−1day−1 astaxanthin (2.38 
mgday−1 in a 70 kg human) based upon research previously conducted in rats (EFSA 
FEEDAP Panel, 2014). This was later reiterated by an EFSA Panel on Dietetic 
Products, Nutrition and Allergies (NDA), where it was concluded that the safety of 4 
mgday−1 astaxanthin (~ 0.06 mgkg−1day−1) had yet to be fully established (EFSA 
NDA Panel, 2014). 
In contrast, no adverse effects were reported in blood pressure or biochemical 
parameters, including a metabolic panel and cell blood count, in 19 healthy 
participants supplementing with 6 mgday−1 astaxanthin for 8 weeks (Spiller and 
Dewell, 2003). Similarly, no adverse effects were also reported in a recent exercise 
study where 16 trained individuals supplemented with 20 mgday−1 astaxanthin for 4 
weeks (Res et al., 2013). The acute intake of 40 mg astaxanthin has also been reported 
as “well-tolerated” in 32 healthy participants with only three mild events in the form 
of headaches reported in the 48 h post-intake (Mercke Odeberg et al., 2003). This was, 
however, in response to a single dose, with information concerning the chronic intake 
of 40 mgday−1 not currently available in a healthy adult cohort. 
Nevertheless, the chronic intake of 16 mgday−1 and 40 mgday−1 astaxanthin has been 
suggested as safe in patients suffering with functional dyspepsia (Kupcinskas et al., 
2008). 131 patients were recruited and randomly assigned either 16 
mgday−1 astaxanthin (n = 43), 40 mgday−1 astaxanthin (n = 44), or an appearance-




during supplementation and a 4 week follow-up, prevalence was not significantly 
different between groups (16 mgday−1: 15 adverse events in 10 patients vs. 40 
mgday−1: 8 adverse events in 7 patients vs. control: 13 adverse events in 7 patients) 
suggesting no additional safety issues (Kupcinskas et al., 2008). As a result, it may be 
possible to safely advocate both acute and chronic intakes of astaxanthin that are 
considerably greater than the current ADI (~ 2.38 mgday−1). Future research is 
therefore required to further elucidate the safety of astaxanthin so that human 
consumption guidelines can be adjusted accordingly. 
 
1.10. Astaxanthin and Exercise Recovery 
The completion of vigorous intensity exercise training sessions and competitive events 
are known to increase numerous physiological stressors, such as muscle damage, 
oxidative stress and inflammation (Leeder et al., 2012). Detriments to the skeletal 
muscle observed in response to the completion of vigorous intensity exercise may, 
therefore, not only result from damage directly induced by RONS, but also damage 
induced through the inflammatory cascade. If recovery is inadequate following 
exercise, it may prevent recreationally active and trained individuals from completing 
the subsequent exercise training sessions required to drive adaptation and/or 
performance improvements. Inadequate recovery may also increase risks of injury, 
illness and overtraining (Roberts et al., 2014). As a result, the investigation of 
strategies that can reduce the negative effect of exercise-induced muscle damage 




Sayers and McHugh, 2003, Howatson and van Someren, 2008, Leeder et al., 2012, 
Hill et al., 2014). 
Through its potency as an antioxidant compound, it is plausible to propose that 
astaxanthin could exert a recovery benefit through the inhibition of both pro-oxidant 
and pro-inflammatory intermediates (Aoi et al., 2003, Lee et al., 2003). In 
vitro research has reported a dose-dependent inhibition of NO and intracellular RONS, 
as well as the H2O2-induced activation of nuclear factor kappa B (NFκB) following 
5–100 µM astaxanthin administration (Lee et al., 2003). Furthermore, 50 µM 
astaxanthin also completely inhibited the stimulation of iNOS and iNOS mRNA. As 
iNOS is predominantly present in many inflammatory conditions (Reid, 2016b), the 
subsequent expression of pro-inflammatory cytokines, such as tumour necrosis factor-
α (TNF-α) and interleukin-1β (IL-1β), were also significantly suppressed (TNF-α: 
−76%; IL-1β: −46%) in comparison to the control (Lee et al., 2003).  
Investigation with in vivo mouse models also report a similar effect following a 
lipopolysaccharide stressor, with significant reductions in plasma NO (−58%), TNF-
α (−50%), and IL-1β (−57%) reported following treatment with a 40 mgkg−1 dose of 
astaxanthin in comparison to the control (Lee et al., 2003). Although the work of Lee 
et al. (2003) was not specific to the recovery response to exercise, it displays a 
potential mechanism by which astaxanthin may promote recovery through inhibiting 
the oxidative and inflammatory responses to a physiological stressor. Supportive 
evidence is, however, received from an exercising mouse model (Aoi et al., 2003). 




supplementation (0.02 ww−1 per 100 g of total dietary intake) attenuated oxidative 
damage to lipid and nucleic acid molecules in the skeletal and cardiac muscle tissue. 
This was evidenced by the substantial decrease of 4-hydroxy-2-nonenal (4-HNE) 
modified protein production, as well as the significant inhibition of 8-hydroxy-2′-
deoxyguanosine (8-OHdG) in the skeletal (−12%) and cardiac (−17%) muscle tissue, 
in comparison to the control (Aoi et al., 2003). Furthermore, 24 h post-exhaustive 
exercise, dietary astaxanthin also significantly decreased the activity of 
myeloperoxidase (MPO) by 50% in the skeletal muscle tissue and 33% in the cardiac 
muscle tissue when compared to the control, as well as significantly reducing creatine 
kinase (CK) activity in the plasma (astaxanthin: 2,617 UL−1 vs. control: 3,032 UL−1) 
(Aoi et al., 2003). As MPO and CK are markers of secondary neutrophil infiltration 
and muscle damage, this also highlights a potential for astaxanthin to attenuate the 
inflammatory muscle damage response in the days following exhaustive exercise. 
The use of in vitro and in vivo mouse models have, therefore, demonstrated an ability 
of astaxanthin to inhibit a series of biomarkers linked to the onset of muscle damage, 
oxidative stress, and/or inflammation. As a result, research has subsequently aimed to 
elucidate whether astaxanthin supplementation possesses the ability to modulate the 
recovery response in an exercising human cohort. In a sample of 20 resistance trained 
males, for example, recovery from a muscle damaging bout of eccentric exercise was 
quantified through perceptions of muscle soreness, concentrations of plasma CK and 
the recovery of one repetition maximum concentric strength, mean isometric force, 
and mean dynamic force  (Bloomer et al., 2005). Although a significant time effect for 




mgday−1 astaxanthin for three weeks prior to exercise was not observed. As young, 
resistance trained males were recruited, however, it is uncertain as to whether this 
outcome could be generalised to less trained individuals or to those participating in 
events other than high-force, resistance exercise.  
Future research should, therefore, aim to address this uncertainty by recruiting 
participants with different training demographics to investigate whether training status 
can confound the efficacy of astaxanthin as a recovery aid post-exercise. More 
recently, markers of muscle damage and oxidative stress were measured in response 
to a 2 h bout of soccer exercise in elite youth male soccer players (n = 32; age: 17–18 
years) following supplementation with 4 mgday−1 astaxanthin for 90 days during the 
regular competitive season (Djordjevic et al., 2012). A supplement effect was not 
reported in exercise-induced changes in plasma CK and generic measures of oxidative 
stress (thiobarbituric acid-reactive substances (TBARS), advanced oxidation protein 
products, superoxide anion, total antioxidant status, sulphydril groups, and SOD), 
suggesting a recovery effect was not present (Djordjevic et al., 2012). 
The same research group later conducted a similar investigation in a separate cohort 
of elite youth male soccer players (n = 40; age: 17–18 years) during the competitive 
season (Baralic et al., 2015). Adherence to exercise training alone over the 90 day 
protocol was reported to significantly attenuate muscle damage, implicated by a 
reduction in both plasma CK (astaxanthin: −44.6%; control: −30.1%) and lactate 
dehydrogenase (LDH) (astaxanthin: −27.4%; control: −18.5%) from baseline 
measures. Astaxanthin supplementation (4 mgday−1) was suggested to augment these 




attenuating training-induced increases in serum C-reactive protein and total leukocyte 
and neutrophil counts, in comparison to the control (Baralic et al., 2015). 
Caution is required however, as a significant supplement effect of astaxanthin was not 
reported in regard to each of the aforementioned variables, apart from the LDH 
biomarker (p < 0.05); suggesting that astaxanthin actually had little effect. 
Furthermore, when attempting to elucidate the effect of astaxanthin on muscle damage 
and recovery responses to exercise, both Djordjevic et al. (2012) and Baralic et al. 
(2015) placed a heavy reliance upon indirect biomarkers such as CK and/or LDH 
obtained from the blood. Both CK and LDH have been reported to possess a large 
inter-individual variance and low reliability in blood concentrations (Connolly, Sayers 
and McHugh, 2003), with the use of muscular force production purported to be a more 
reliable marker of skeletal muscle injury (Warren, Lowe and Armstrong, 1999, 
Connolly, Sayers and McHugh, 2003). Future research should, therefore, be conducted 
with the use of more reliable analytical methods so that a comprehensive conclusion 
can be made regarding astaxanthin and the attenuation of exercise-induced muscle 
damage in exercising humans. 
 
1.11. Astaxanthin and Exercise Metabolism 
The metabolism of fat as an energy source is dependent upon the entry of long-chain 
fatty acids into the mitochondria; a process requiring the mitochondrial carnitine 
palmitoyltransferase (CPT) complex and in particular the CPT1 regulatory enzyme 
(Yeo et al., 2011). During exercise, RONS-induced oxidative damage to CPT1 can 




consequently limiting the ability for fats to be oxidised as a viable energy source (Aoi 
et al., 2008). Due to its lipophilic properties, astaxanthin is known to accumulate in 
the mitochondrial membrane following consumption and provide a protection against 
RONS-induced detriments to its function (Wolf et al., 2010, Kidd, 2011). It is, 
therefore, hypothesised that through its function as an antioxidant, astaxanthin could 
protect CPT1 against RONS-induced oxidative modifications, causing an indirect 
enhancement of exercising fat metabolism in the process (Aoi et al., 2008). 
Aoi et al. (2008) investigated this hypothesis with the use of an exercising mouse 
model. In comparison to the control, 4 weeks of astaxanthin supplementation (0.02% 
ww−1) significantly enhanced the coimmunoprecipitation of fatty acid translocase 
(FAT)/CD36 and CPT1 by 14.5% due to a concomitant and significant 41.4% decrease 
in the oxidative modification of CPT1. Muscle glycogen concentrations were also 
significantly greater in the astaxanthin group (2.7 ± 0.1 mgg−1 tissue) in comparison 
to the control (2.3 ± 0.1 mgg−1 tissue) and plasma non-esterified fatty acid (NEFA) 
concentrations tended to be higher (astaxanthin group: 1.05 ± 0.05 mEqL−1 vs. control 
group: 0.94 ± 0.05 mEqL−1), suggesting a potential glycogen sparing effect (Aoi et 
al., 2008). In a separate cohort of mice undertaking the same supplementation 
protocol, the respiratory exchange ratio (RER) was significantly lower from 20 min 
onward during a 60 min run (25 mmin−1), with corresponding measures of fat 
oxidation (mgkg−1min−1) also significantly higher (+21%) and carbohydrate 
oxidation (mgkg−1min−1) significantly lower (-12%) when compared to the control 




As a result, it was concluded that through its potency as an antioxidant compound, 
astaxanthin is able to indirectly enhance the utilisation of fats during exercise through 
increasing the intercalation of FAT/CD36 and CPT1 on the mitochondrial membrane 
(Aoi et al., 2008). Similar findings are also reported in a swimming mouse model 
(Ikeuchi et al., 2006). On completion of a 15 min swim against an additional 5% body 
mass, for example, mice supplemented with 6 and 30 mgkg−1 astaxanthin for 3 weeks 
had significantly greater concentrations of plasma glucose (6 mgkg−1: 124 mgdL−1 
vs. 30 mgkg−1: 135 mgdL−1 vs. control: 104 mgdL−1), with plasma NEFA also 
significantly elevated throughout exercise in the 30 mgkg−1 astaxanthin group. Muscle 
glycogen concentrations were also significantly greater post-exercise following 5 
weeks of supplementation with 6 and 30 mgkg−1 astaxanthin (6 mgkg−1 group: 4.0 
mgg−1 vs. 30 mgkg−1 group: 4.2 mgg−1 vs. control group: 3.4 mgg−1), with 
corresponding measures of liver glycogen concentrations also significantly greater in 
the 30 mgkg−1 group (30 mgkg−1: 49.8 mgg−1 vs. control: 40.7 mgg−1). 
In contrast, a significant decrement in plasma NEFA concentration has been reported 
following the completion of a 30 min run at 25 mmin−1 in mice supplemented with 
0.02 ww−1 astaxanthin for 2 weeks (astaxanthin group: 905 ± 41 mEqL−1 vs. control 
group: 1,151 ± 61 mEqL−1) (Liu et al., 2014). Although the authors speculated that 
this resulted from increased utilisation within the skeletal muscle, no direct 
measurement was made (Liu et al., 2014). Furthermore, despite a tendency for plasma 
glucose to be higher post-exercise in the astaxanthin group (astaxanthin group: 121 ± 




not reported, suggesting that astaxanthin did not exert a glycogen-sparing effect  (Liu 
et al., 2014). 
More recently, the metabolic mechanism of astaxanthin has been explored further in 
mice supplemented with H. pluvialis-derived astaxanthin (0.02 ww−1) for 5 weeks 
(Aoi et al., 2018). Although indices of exercise metabolism were not measured in this 
study, levels of the regulatory enzyme 5' adenosine monophosphate-activated protein 
kinase (AMPK) were determined in the skeletal muscle post-supplementation through 
western-blotting. As a key regulator of skeletal muscle metabolism, AMPK is 
implicated in the stimulation of fatty acid oxidation through its control of malonyl-
CoA and suppression of acetyl co-enzyme A carboxylase; the transportation of fatty 
acids into the mitochondria, potentially through FAT/CD36; as well as the 
upregulation of many transcription factors, such as peroxisome proliferator-activated 
receptor-γ coactivator-1α (PGC-1α), that are known to promote mitochondrial 
biogenesis and control mitochondrial oxidative capacity (Thomson and Winder, 
2009). As mice in the astaxanthin group expressed a significantly greater level of 
skeletal muscle AMPK post-supplementation (p < 0.05), a potential mechanistic 
insight into how astaxanthin is able to enhance fat metabolism during exercise is 
provided (Aoi et al., 2018).  
Evidence from exercising mice models would therefore suggest that 3–5 weeks of 
astaxanthin supplementation potentially exerts a metabolic benefit through enhancing 
fat utilisation and attenuating muscle glycogen depletion during endurance-type 
exercise (Ikeuchi et al., 2006, Aoi et al., 2008). It should, however, be noted that 




(Shanks, Greek and Greek, 2009). Interestingly, a similar metabolic effect has yet to 
be replicated within an exercising human cohort (Earnest et al., 2011, Res et al., 2013). 
Four weeks of 4 mgday−1 astaxanthin supplementation, for example, did not influence 
parameters of substrate metabolism (such as RER, carbohydrate and fat oxidation 
rates, and plasma glucose and NEFA concentrations) obtained during 2 h of 
submaximal cycling (5% below lactate threshold) in trained male cyclists (n = 
14; VO2peak ≥ 50 mL.kg
−1.min−1) (Earnest et al., 2011). 
The 4 mgday−1 dose issued, however, was trivial in comparison to the 6–30 mgkg−1 
doses that have been previously prescribed in a mouse model (Ikeuchi et al., 2006). 
To elicit a similar metabolic modulation as previously reported in a mouse model, it 
was hypothesised that a dose greater than 4 mgday−1 would be required in an 
exercising human cohort (Res et al., 2013). As a result, Res et al. (2013) recruited 
trained male cyclists or triathletes (VO2peak: 60 ± 1 mLkg
−1min−1) to a 4 week 
supplementation protocol consisting of either 20 mgday−1 astaxanthin, or an 
appearance-matched control in a double-blind, parallel design (n = 16 astaxanthin 
group; n = 15 control group). Despite a fivefold increase in dose, measures of RER, 
carbohydrate and fat oxidation rates, and concentrations of plasma glucose and free 
fatty acids were again not significantly affected during the completion of a 1 h steady-
state cycle at 50% of maximal power output (Wmax) (Res et al., 2013). Based upon this 
evidence, it would therefore appear that 4 weeks of astaxanthin supplementation does 
not exert a metabolic effect during endurance exercise, even at greater levels of intake, 




Res et al. (2013) also detected no measurable changes in the plasma concentrations of 
the lipid peroxide malondialdehyde (MDA) during exercise, suggesting an antioxidant 
effect of astaxanthin was not present. Although speculative, this observation may 
provide an insight as to why a metabolic effect was not reported in this study, with 
previous research suggesting that an indirect metabolic modulation is mediated 
through the antioxidant protection of CPT1 from astaxanthin (Aoi et al., 2008). The 
lack of a direct antioxidant effect and the corresponding metabolic effect, reported by 
Res et al. (2013), may be attributable to either the high training and fitness 
demographics of the participants recruited (VO2peak: 60 ± 1 mLkg
−1min−1; training 
frequency: > 3 sessionsweek−1 for ≥ 2 years) or the length of the supplementation 
period undertaken within this study (Res et al., 2013).  
In trained individuals, for example, a reduction in RONS production is commonly 
reported at any given exercise intensity, with regular endurance-type exercise training 
also associated with decreased levels of lipid peroxidation due to an increased capacity 
of the endogenous antioxidant defence system (Radak et al., 2013). As such, Res et al. 
(2013) speculated that the improvements in endogenous antioxidant defence, induced 
by regular endurance-type exercise training, may attenuate the potential for additional 
improvements provided by astaxanthin supplementation. Concentrations of MDA, 
however, are reported to decrease significantly in sedentary individuals following 20 
mgday−1 astaxanthin for both 8 (astaxanthin group: 1.72 ± 0.28 µmolL−1 vs. control 
group: 2.08 ± 0.12 µmolL−1) and 12 weeks (astaxanthin group: 1.42 ± 0.29 
µmolL−1 vs. control group: 2.00 ± 0.24 µmolL−1), respectively (Choi, Youn and Shin, 




reported to attenuate markers of lipid peroxidation in healthy untrained males (Karppi 
et al., 2007), suggesting that the demographics of participants may be a confounding 
variable for the antioxidant action, and therefore the corresponding metabolic effect, 
of astaxanthin.  
Furthermore, the rate at which fat is oxidised during exercise is also subject to large 
inter-individual variations, even at the same absolute and relative intensities 
(Goedecke et al., 2000, Achten, Gleeson and Jeukendrup, 2002, Venables, Achten and 
Jeukendrup, 2005). The exercise intensity at which fat oxidation is maximal (FATmax) 
is also highly variable between individuals (Goedecke et al., 2000, Venables, Achten 
and Jeukendrup, 2005). In 300 healthy men and women, for example, FATmax values 
in the range of 25 and 77% VO2max were reported despite an average value of 48 ± 
1% VO2max reported overall (Venables, Achten and Jeukendrup, 2005). Consequently, 
if fat oxidation is measured at a constant steady-state intensity, the ability to determine 
the true effect of a nutritional intervention may be diminished as some individuals will 
be exercising above and others below the exercise intensity at which FATmax is 
elicited. Future research should consider participant demographics, the 
supplementation protocols administered, as well as incorporating sensitive 
measurements of exercising substrate utilisation. This may include employing an 
experimental protocol capable of detecting changes in metabolism across a range of 
exercise intensities (Achten, Gleeson and Jeukendrup, 2002, Venables, Achten and 
Jeukendrup, 2005), so that the metabolic effect of astaxanthin can be explored in more 





1.12. Astaxanthin and Exercise Performance 
During endurance exercise, the depletion of muscle glycogen is commonly reported 
in the aetiology of fatigue; as such, methods aimed at attenuating this depletion, may 
provide an ergogenic benefit through delaying fatigue onset (Coyle et al., 1986). A 
metabolic mechanism that could potentially convey this benefit is the utilisation of fat 
as an alternative energy source to glycogen during exercise (Yeo et al., 2011). With 
previous research conducted in mice illustrating such a metabolic effect (Ikeuchi et 
al., 2006, Aoi et al., 2008), a potential for astaxanthin to act as an ergogenic aid during 
the performance of endurance exercise has been hypothesised (Ikeuchi et al., 2006, 
Aoi et al., 2008, Earnest et al., 2011, Res et al., 2013). 
Ikeuchi et al. (2006) conducted a series of experiments in mice to investigate the 
ergogenic potential of astaxanthin (1.2, 6, or 30 mgkg−1) on swim time to exhaustion 
(TTE). In the first experiment, mice undertook a weekly swim TTE against an 
additional 10% body mass over a 5 week supplementation period. In comparison to 
the control, a continuous significant improvement in TTE was observed from the first 
week onward in the mice supplemented with 6 mgkg−1 (p < 0.01) and 30 mgkg−1 (p < 
0.05) astaxanthin. After 5 weeks, this significant improvement was observed in a dose-
dependent manner across all astaxanthin groups with an ergogenic benefit also 
reported in the 1.2 mgkg−1 astaxanthin group (1.2 mgkg−1 group: 2.27 min vs. 6 
mgkg−1 group: 3.32 min vs. 30 mgkg−1 group: 5.12 min vs. control group: 1.44 min) 
(Ikeuchi et al., 2006). 
Similar results were also reported in a separate cohort of mice, as 3 weeks of 6 and 30 




additional 5% body mass (6 mgkg−1 group: 27.50 ± 3.04 min vs. 30 mgkg−1 group: 
36.06 ± 4.13 min vs. control group: 19.45 ± 2.02 min) (Ikeuchi et al., 2006). Further 
support is also evident from running mice-models, as mice fed daily with 0.02 
ww−1 astaxanthin for 4 weeks were able to significantly enhance TTE at a running 
intensity of 30 mmin−1 by 34% (67.53 ± 4.20 min) in comparison to the exercising 
control (50.40 ± 5.00 min) (Aoi et al., 2008). A similar improvement in TTE at a 
running intensity of 25 mmin−1 was also reported in mice fed daily with H. pluvialis-
derived astaxanthin (0.02 ww−1) for 5 weeks when compared to mice fed with either 
synthetic (p = 0.032) or Phaffia yeast-derived sources (p = 0.015) (Aoi et al., 2018). 
In comparison to the control, however, despite a 73% improvement in running TTE 
reported in the mice fed H. pluvialis-derived astaxanthin, this improvement did not 
reach statistical significance (p = 0.106, n = 5 each group); suggesting a supplement 
effect may not have been present (Aoi et al., 2018). 
Based upon in vivo work conducted in mice, it therefore appears that 3-5 weeks of 
astaxanthin intake exerts an ergogenic benefit during the performance of endurance 
exercise; an ability attributed to its aforementioned effect on substrate metabolism 
(Ikeuchi et al., 2006, Aoi et al., 2008). In humans, a similar ergogenic benefit was 
reported in trained male cyclists (n = 14; VO2peak > 50 mLkg
−1.min−1; weekly cycling 
volume > 160 kmweek−1), as 4 weeks of astaxanthin supplementation (4 mgday−1) 
significantly improved 20 km cycling time trial (TT) performance when compared to 
baseline (baseline: 39.47 ± 3.26 min vs. 4 weeks: 37.46 ± 3.10 min) (Earnest et al., 
2011). Furthermore, the 121 s time improvement (5.1%) reported in the astaxanthin 




reported in the control (baseline: 37.31 ± 4.20 min vs. 4 weeks: 37.13 ± 4.43 min), 
suggesting a treatment effect was present (p < 0.05; effect size: 1.25) (Earnest et al., 
2011). 
In contrast, an ergogenic benefit was not reported during a 1 h cycling TT in trained 
male cyclists or triathletes (n = 31; VO2peak: 60 ± 1 mLkg
−1min−1; training frequency: 
> 3 sessionsweek−1 for > 2 years) following a 4 week supplementation with either 20 
mgday−1 astaxanthin (baseline: 60.38 ± 1.20 min vs. 4 weeks: 59.14 ± 1.21 min) or 
an appearance-matched control (baseline: 59.43 ± 1.37 min vs. 4 weeks: 58.57 ± 1.39 
min) (Res et al., 2013). Although there is no clear explanation for the disparity 
between the two findings, it should be noted that a metabolic mechanism was not 
reported by either study (Earnest et al., 2011, Res et al., 2013). As the enhancement 
of fat metabolism and the subsequent sparing of muscle glycogen are the suggested 
mechanisms by which astaxanthin exerts its ergogenic potential, the absence of this 
effect may implicate an alternative ergogenic mechanism in Earnest et al. (2011), or 
partially explain the absence of a performance effect in Res et al. (2013). 
It is plausible, however, that the heterogeneity of the sample in Earnest et al. (2011) 
may have contributed to the disparity reported between studies with regards to TT 
performance. Participants (n = 7 each group) were randomly assigned to each 
treatment group and although a full familiarisation was completed, and baseline fitness 
characteristics appeared to be similar, the standard deviation (SD) of each 20 km TT 
(190–283 s) was far greater than the 136 s time improvement reported in the 
astaxanthin group. To ensure the reliability of the performance outcome reported, the 




not available, it is difficult to conclude whether the time improvement reported in the 
astaxanthin group (5.1%) resulted from a significant supplement effect or the variation 
present in the study protocol. Previously, a coefficient of variation (CV) of 1.5% (± 
10% confidence intervals: 1.1–2.1%) has been reported for the performance of a 20 
km TT separated by 4 weeks in 19 trained cyclists (> 2 years racing experience at an 
A or B grade standard) (Clark et al., 2014). If a similar re-test reliability would have 
been reported by Earnest et al. (2011), the ergogenic effect of astaxanthin could be 
inferred as the performance improvement during the 20 km TT would have been 
greater than the CV reported. Future research should, therefore, seek to confirm 
whether an ergogenic potential of astaxanthin is present within an exercising human 
cohort, with a particular emphasis placed upon implementing a valid and reliable 
testing protocol to ensure that a robust conclusion can be made. In comparison to 
previous performance studies, future research should also consider implementing 
performance tests of a longer duration (>1 h), allowing the ergogenic potential of 
astaxanthin to be investigated during the completion of an exercise bout that may 
reflect the proposed mechanism of action more appropriately. 
 
1.13. Summary and Research Aims 
This review of literature has introduced three main research themes, namely the effect 
of astaxanthin on indices of exercise recovery, metabolism and performance. 
Together, these themes will inform the experimental investigations of this thesis. 
Previously, in vitro and in vivo animal models have provided evidence to support the 




models, improvements in the acute recovery from exercise-induced muscle damage, 
substrate utilisation and endurance performance are reported following 3-5 weeks of 
astaxanthin intake; with each function attributed in part to the potent antioxidant 
capacity of this xanthophyll carotenoid. In exercising humans, however, these 
observations have yet to be consistently realised, with equivocal data reported. This 
thesis will attempt to address some of these issues with the following research aims 
and methodologies, written up as part of the proceeding three experimental chapters. 
Study 1 (Chapter 3): Synonymous with downhill running exercise, muscular 
contractions that incorporate an eccentric component are often reported to cause 
significant microstructural damage due to repeatedly forcing the muscle to 
lengthen under tension (Proske and Allen, 2005). As such, the use of eccentric 
exercise protocols (such as downhill running) as a method of inducing muscle 
damage/soreness has become increasingly common in research aiming to 
investigate the recovery benefits of different nutritional interventions (Close et al., 
2006, Mcleay et al., 2012, Hutchison et al., 2016). A 30 min downhill run, similar 
those conducted previously (Close et al., 2004, 2006), was used in Chapter 3 as an 
experimental protocol capable of inducing various markers of exercise-induced 
muscle damage and soreness so that the acute recovery function of astaxanthin 
could be investigated in a group of recreationally active male participants. 
Therefore, the aim of Chapter 3 was to investigate whether a prolonged 
supplementation with astaxanthin (4 mgday−1 and 12 mgday−1) for 8 weeks could 




damage/injury in the 48 h following a 30 min downhill run in recreationally active 
males. 
 
Study 2 (Chapter 4): The FATmax protocol was utilised in Chapter 4  as a 
previously validated, accurate and relatively reliable (CV: 9.6%) description of fat 
oxidation over a wide range of exercise intensities (Achten, Gleeson and 
Jeukendrup, 2002). This protocol, conducted on a treadmill, gradually increases 
the intensity (walking/running speed) of exercise until volitional exhaustion, with 
corresponding rates of fat oxidation quantified using indirect calorimetry. This 
ability to describe fat oxidation over a wide range of exercise intensities enables 
the determination of various parameters pertaining to the fat oxidative capacity; 
including the maximal fat oxidation rate (MFO) and the exercise intensity (% 
VO2peak and % HRmax) at which this occurs (FATmax). As such, the FATmax protocol 
provided an experimental means to investigate the metabolic effect of astaxanthin 
on individual substrate utilisation across various exercise intensities and time 
points during supplementation. 
As such, the aim of Chapter 4 was to investigate whether 4 weeks or 8 weeks of 
astaxanthin supplementation (4 mgday−1 and 12 mgday−1) could enhance the fat 
oxidative capacity, namely the MFO and FATmax, during the completion of a 
FATmax protocol in a group of recreationally active males. 
 
Study 3 (Chapter 5): In Chapter 5, a 40 km cycling TT was chosen as an 




1996, Laursen, Shing and Jenkins, 2003, Currell and Jeukendrup, 2008). Indeed, 
previous research quantifies the test re-test reliability of the 40 km cycling TT as 
1.0 ± 0.5% (Palmer et al., 1996) and 0.9 ± 0.7% following an initial familiarisation 
in trained male cyclists (Laursen, Shing and Jenkins, 2003). This high 
reproducibility, alongside the prolonged duration of the 40 km cycling TT (> 1 h), 
may provide a more appropriate experimental protocol to investigate the ergogenic 
potential of astaxanthin in exercising humans. 
Therefore, the aim of Chapter 5 was to investigate whether a shorter 7 day intake 
of astaxanthin (12 mgday−1) could improve exercise performance and metabolism 














The purpose of the following chapter is to provide an outline of the general procedures 
that are consistent across all trials conducted in this thesis. This includes a description, 
justification and where necessary, the test re-test reliability of each procedure utilised. 
In Chapters 3-5, a more specific description of the methodologies and experimental 
designs employed are provided. 
 
2.1. Ethical Considerations 
Ethical approval was obtained for all studies in this thesis from the Department of 
Sport and Physical Activity Research Ethics Committee and the University Research 
Ethics Sub-Committee at Edge Hill University. If blood samples were collected and 
stored, this was practiced in accordance to the local Human Tissue Authority license 
regulations. Prior to study onset, all participants were first provided with a written 
information document detailing the procedures, benefits and risks of each study. 
Following a sufficient time to consider participation (usually 24 h), an opportunity to 
ask questions regarding the study was provided. If a participant agreed to volunteer, 
written informed consent was provided detailing this decision. 
In accordance with Edge Hill University guidelines all participants completed a 
general health screening questionnaire prior to study onset to determine clearance to 
exercise. Participants with asthma were also required to present medication prior to 
exercise, with those advised against exercise by a doctor excluded. Participants also 
completed a health screening assessment before each exercise trial. This involved 
measuring resting blood pressure and heart rate (HR) with inclusion criteria set at < 




beatsmin−1 (HR). If any measure exceeded this criteria exercise was not be permitted, 
with the participant advised to seek medical clearance to exercise. This was done to 




Healthy adult males between the ages of 18-45 years old were recruited to participate 
in each study. During participation, supplementation with additional forms of 
antioxidants/vitamins other than those provided in each study was not permitted. A 
list of commonly consumed astaxanthin-rich foods to avoid was also provided to limit 
the additional dietary intake of astaxanthin during supplementation. 
Participant training status in each study was classified in accordance with the criteria 
outlined by De Pauw et al. (2013). As such, participants in Chapters 3 and 4 are 
referred to as recreationally active due to participating in a regular exercise regime 
that represents a volume of work that is > 4 hweek−1. In Chapter 5, participants are 
referred to as “recreationally trained cyclists”, as although the VO2peak (56.5 ± 5.5 
mLkg−1min−1) and Wmax (347 ± 38 W) of the sample met the criteria required to be 
classified as a “trained cyclist”, the criteria required for total distance covered (60-290 
kmweek−1) and cycling training frequency (> 3 timesweek−1) was not met. As such, 
the term “recreationally trained cyclist” was deemed to be most appropriate for the 





2.3. Pre-Experimental Procedures 
Before each experimental trial participants undertook several standardised procedures 
to limit the confounding effects of nutrition, hydration status and day-to-day variations 
in the physiological response to exercise. Each experimental trial, for example, was 
conducted at a similar time of day (± 1 h) to account for the influence of circadian 
rhythm on exercise performance (Reilly, 1990). Participants were also instructed to 
refrain from strenuous exercise and the consumption of alcohol and caffeine in the 24 
h preceding each visit (Rosenberg et al., 1978, Westerterp-Plantenga et al., 2006). A 
normal habitual diet was maintained in each study; however, participants were 
required to enter the laboratory in either a 4 h postprandial state (Chapters 3 and 5) or 
following an overnight fast (~ 10 h) (Chapter 4), except for the ingestion of water to 
ensure euhydration. Compliance with the above procedures was checked via 24 h 
dietary recall, with participants asked to replicate dietary intake prior to each trial.  
 
2.4. Treatment 
In Chapters 3 and 4 a parallel groups design was employed, with participants matched 
based upon characteristics pertinent to both performance capabilities (i.e. VO2peak, 
FATmax) and physical characteristics (i.e. age, body mass, body fat). Each matched 
group supplemented with one of three treatments for the entirety of the 
supplementation protocols (4 or 8 weeks). Treatment consisted of either 4 
mgday−1 astaxanthin, 12 mgday−1 astaxanthin or an appearance-matched placebo 
with no viable constituents. In Chapter 5 a randomised, double-blind crossover design 




appearance-matched placebo with no viable constituents for the 7 days preceding each 
experimental trial. A 14 day washout period interspersed each supplementation period. 
The use of a parallel groups design in Chapters 3 and 4 was required due to the 
implementation of a chronic supplementation protocol. It is accepted that this 
experimental design has less power than a randomised crossover design (as employed 
in Chapter 5) due to inter-individual variability (Burke and Peeling, 2018); however, 
this was somewhat controlled by the careful allocation of participants to each parallel 
group in each study as detailed above. In contrast, the shorter supplementation strategy 
implemented in Chapter 5 enabled the use of a randomised crossover design with each 
participant able to act as their own control. This is potentially advantageous, as it 
minimises the potential impact subtle differences in participant characteristics and 
individual responses to astaxanthin could have upon the outcome variable, increasing 
the statistical power of this study design (Cleophas and de Vogel, 1998, Burke and 
Peeling, 2018).  
To reduce the potential of a carryover effect, whereby the treatment provided prior to 
the first experimental trial influences the outcome of the second experimental trial, the 
use of an appropriate washout period was paramount when conducting a randomised 
crossover design (Burke and Peeling, 2018). As such, the washout period undertaken 
in Chapter 5 was estimated based upon the calculations obtained from Saha (2018), 
which state that > 99.9% of a drug or treatment is eliminated after a period of time 
equivalent to 10 half-lives. Using the half-life of 15.9 ± 5.3 h, reported in Mercke 
Odeberg et al. (2003), it was estimated that > 99.9% of the total astaxanthin consumed 




estimation, however, a more conservative 14 day washout period was decided upon to 
ensure the elimination of astaxanthin prior to the second experimental trial. 
The treatments administered in each study were produced and blister packaged by the 
pharmaceutical company AstaReal® (Sweden). Participants ingested two capsules 
daily (one morning and one evening), with compliance ensured via daily text message 
reminders and a pill count post-ingestion. Each treatment also had a randomised code 
assigned to it, ensuring that all studies were double-blind until after data analysis was 
complete. The 12 mgday−1 dose administered in each experimental chapter was the 
maximal dose available to administer as stipulated by the manufacturer (AstaReal®, 
Sweden). 
 
2.5. Environmental Conditions 
All exercise trials in this thesis were performed in a temperate laboratory environment 
(temperature: 19 ± 2 C; pressure: 753 ± 9 mmHg, humidity 45 ± 4%). 
 
2.6. Anthropometric Measurements 
On entering the laboratory height was measured using a stadiometer (Holtain, UK) 
and is subsequently reported in metres (m). Body mass (kg) and body fat (%) were 
measured using an air displacement plethysmography device (BodPod, Cosmed, 
Italy), with data reported to the nearest 0.1 kg/%. Prior to each measurement, 
calibration was carried out in accordance with the guidelines set by the manufacturer. 




techniques, such as dual-energy x-ray absorptiometry (Minderico et al., 2006), and is 
also reported to possess a high test re-test reliability for both within-day (reliability 
coefficient: 0.992-0.994) and between-days (reliability coefficient: 0.996) 
measurements obtained from healthy male participants (Tseh, Caputo and Keefer, 
2010). 
 
2.7. Heart Rate 
To enable the continuous monitoring of heart rate participants wore a heart rate 
transmitter belt across their chest, level with the xiphoid process, which was 
subsequently connected to a telemetric monitoring system (Forerunner 15, Garmin, 
USA). Heart rate was recorded at several time points during each trial, with further 
descriptions provided in each study chapter. 
 
2.8. Perceptual Variables 
Ratings of perceived exertion (RPE) were assessed during exercise on a 6-20 point 
scale, with verbal descriptors provided to ensure that participants were able to select 
the appropriate rating (Borg, 1982). In Chapters 3 and 5, RPE was differentiated into 
ratings for overall cardiovascular strain (RPEO) and for the lower limb musculature 
(RPEL) to ensure that a rating of both central and localised fatigue/exertion could be 
obtained (Faulkner and Eston, 2007). This was particularly important in Chapter 5 as 
sensations of localised muscle fatigue in the legs have been reported to dominate the 
assessment of effort perception during cycling (Borg, Ljunggren and Ceci, 1985, 




2.9. Gas Analysis 
Breath-by-breath expired air was collected and analysed during each exercise trial 
with the use of an online gas analysis system (Oxycon Pro, Jaeger, Germany). The 
Oxycon Pro has previously been reported to be both valid and reliable, possessing a 
relatively low CV of 4.7-7.0% (Carter and Jeukendrup, 2002). Prior to each use, the 
system was calibrated in accordance with instructions set by the manufacturer. Gas 
analysers were calibrated using known gas concentrations (16.0% oxygen, 5.0% 
carbon dioxide), whilst volume calibration was conducted using a 3 L syringe (Hans 
Rudolph, USA) and the automated 2 L system setting. As data were collected 
continuously throughout exercise in Chapters 3 and 4, participants were required to 
wear a face mask (Hans Rudolph, USA) during exercise. In Chapter 5, as expired air 
was not collected continuously a face mask was not required, with a nose-clip and 
mouthpiece used when expired air samples were required at each data collection time 
point. 
 
2.10. Determination of VO2peak 
All participants completed a graded incremental exercise test (GXT) to volitional 
exhaustion to enable the determination of peak oxygen uptake (VO2peak) during 
exercise. In Chapters 3 and 4 the GXT was conducted on a motorised treadmill (H-P 
cosmos, Germany) and commenced at a speed of 3.5 kmh−1 and a gradient of 1.0%. 
Speed was then increased by 1.0 kmh−1 every 3 min until a RER of 1.00 was reached, 
at which point speed remained constant and the gradient was increased by a further 




reached volitional exhaustion, the gradient was then kept constant and the speed was 
increased by 1.0 kmh−1 until volitional exhaustion was achieved. In Chapter 5 the 
GXT was conducted using an electromagnetically braked cycle ergometer (Lode 
Excalibur Sport, The Netherlands). Following 5 min of unloaded pedalling, the GXT 
commenced at 75 W and work rate was increased by 30 W every 1 min until volitional 
exhaustion. Participants selected a preferred cadence to maintain throughout, with 
volitional exhaustion defined as an inability to maintain > 60% of this cadence for > 
5 s despite strong verbal encouragement. Breath-by-breath expired air was collected 
throughout each GXT for VO2peak determination (OxyCon Pro, Germany). During 
analysis, data was averaged into 10 s intervals, with VO2peak defined as the highest 30 
s average of VO2 obtained during the GXT. 
 
2.11. Indirect Calorimetry 
Indirect calorimetry is a method of determining whole-body substrate oxidation rates 
using measurements of oxygen consumption (VO2) and carbon dioxide excretion 
(VCO2). In Chapters 3 and 5, whole-body fat oxidation rates (FATox) were calculated 
using the VO2 and VCO2 data obtained during exercise, with whole-body 
carbohydrate oxidation rates (CHox) also calculated in Chapter 5. The following 
stoichiometric equations proposed by Jeukendrup and Wallis (2005) were used, 
assuming protein oxidation during exercise is negligible: 
FATox (gmin−1) = 1.695*VO2 – 1.701*VCO2 




The respiratory exchange ratio (RER) was also calculated using the following equation 
as an indirect measure of substrate utilisation during exercise: 
RER = VCO2 / VO2 
To completely oxidise 1 mol of glucose 134 L of oxygen is required and this produces 
134 L of carbon dioxide. An RER of 1.00 is therefore indicative of glucose/ 
carbohydrate being the predominant fuel source (134 L/134 L = 1.00). For the 
complete oxidation of 1 mol of palmitic acid 515 L of oxygen is required and this 
produces 358 L of carbon dioxide. An RER of 0.70 is therefore indicative of palmitic 
acid/fat being the predominant fuel source (358 L/515 L = 0.70) (Jeukendrup and 








3. The Effect of Two Doses of Astaxanthin Supplementation on 
Indices of Exercise-Induced Muscle Damage and Recovery in 





Muscular contractions that incorporate an eccentric component are often implicated in 
the aetiology of exercise-induced muscle damage due to repeatedly forcing the muscle 
to lengthen under tension (McHugh et al., 1999, Proske and Morgan, 2001). 
Synonymous with resistance training and downhill walking/running, detriments to 
muscular function and performance are often exhibited (Proske and Allen, 2005), with 
the concomitant production of RONS and inflammatory intermediates implicating 
further damage, delaying the recovery process and contributing to the delayed onset 
of muscle soreness (DOMS) (Close et al., 2004, Mcleay et al., 2012). If recovery is 
inadequate following exercise, it can prevent recreationally active and trained 
individuals from completing the subsequent exercise training sessions required to 
drive adaptation and/or performance improvements. Inadequate recovery can also 
increase risks of injury, illness and overtraining (Roberts et al., 2014). As a result, 
recovery strategies aimed toward alleviating symptoms of exercise-induced muscle 
damage and/or accelerating the recovery process continue to receive widespread 
research interest in sport nutrition and exercise physiology (Connolly, Sayers and 
McHugh, 2003, Howatson and van Someren, 2008, Leeder et al., 2012, Hill et al., 
2014). 
Through its potency as an antioxidant compound, it is plausible that astaxanthin could 
exert a recovery benefit through inhibiting both pro-oxidant and pro-inflammatory 
intermediates (Aoi et al., 2003, Lee et al., 2003). Evidence from both in vitro and in 
vivo mouse experimental models support this notion, demonstrating an ability for 




oxidative stress, and/or inflammation (Aoi et al., 2003, Lee et al., 2003). In exercising 
humans these observations have yet to be realised, with a supplement effect of 4 
mgday−1 astaxanthin not reported in resistance trained males or elite youth male 
soccer players following 3 weeks and 90 days of supplementation, respectively 
(Bloomer et al., 2005, Djordjevic et al., 2012, Baralic et al., 2015). In Bloomer et al. 
(2005), however, the authors suggested that because resistance trained males were 
recruited, it is uncertain as to whether a similar no effect of astaxanthin would be 
reported in individuals unaccustomed to high-force resistance exercise. This is likely 
due to the repeated-bout effect, whereby regular adherence to muscle damaging bouts 
of resistance training may actually provide a protective adaptation, attenuating the 
muscle damage response to future exercise sessions (Proske and Allen, 2005). The 
current study, therefore, recruited recreationally active males unaccustomed to 
eccentric exercise and high-force resistance training, with the aim of investigating 
whether 4 mgday−1 or an increased 12 mgday−1 dose of astaxanthin for 8 weeks can 
attenuate the muscle damage response and/or accelerate the recovery process in the 48 
h following a 30 min bout of eccentric exercise. 
 
3.2. Methods 
3.2.1.  Participants 
Twenty-five recreationally active males (age: 26 ± 5 years, height: 1.79 ± 0.05 m, body 
mass: 82.0 ± 9.1 kg, body fat: 17.1 ± 3.5%) provided written informed consent and 
participated in the study. All participants were unaccustomed to eccentric 




supplement with additional antioxidants/vitamins alongside those provided in the 
current study. A list of commonly consumed astaxanthin-rich foods to avoid was also 
provided to limit the additional dietary intake of astaxanthin during supplementation. 
Participants were also instructed to refrain from strenuous exercise and the 
consumption of alcohol and caffeine in the 24 h preceding each visit (Rosenberg et 
al., 1978, Westerterp-Plantenga et al., 2006), and to enter the laboratory in a 4 h 
postprandial state, except for the ingestion of water to ensure euhydration. 
Compliance with the above procedures was checked via 24 h dietary recall, with 
participants asked to replicate dietary intake prior to each trial. In addition, participants 
were also instructed to not undertake any form of therapeutic intervention used to 
alleviate symptoms of muscle soreness in the days leading up to and following the 
downhill run. All participants visited the laboratory at a similar time of day (± 1 h) on 
five separate occasions (two preliminary trials and three experimental trials). A 
double-blind parallel-groups design was employed. 
 
3.2.2.  Preliminary Trials 
On entering the laboratory measures of height and body mass were obtained, with 
body composition also determined using air displacement plethysmography. 
Participants then completed a GXT to volitional exhaustion on a motorised treadmill. 
The GXT commenced at a speed of 3.5 kmh−1 and a gradient of 1.0%. Speed was then 
increased by 1.0 kmh−1 every 3 min until a RER of 1.00 was reached, at which point 
speed remained constant and the gradient was increased by a further 1.0% every min 




exhaustion, the gradient was then kept constant and the speed was increased by 1.0 
kmh−1 until volitional exhaustion. Breath-by-breath expired air was collected for 
VO2peak determination and was defined as the highest 30 s average of VO2 recorded 
during the GXT. Following a short period of rest, participants were then familiarised 
with the Isokinetic Dynamometer (IKD) protocol used during each experimental trial 
(as described in 3.2.5. Determination of Isokinetic Maximal Voluntary Contraction 
Strength). Participants completed this preliminary trial on two separate occasions, 
once at baseline and once more during the eighth week of supplementation. This was 
to ensure that each participant could be re-familiarised with the IKD protocol, but also 
to ensure that any changes in VO2peak and/or isokinetic MVC could be highlighted 
before the first experimental trial. 
 
3.2.3.  Group Matching 
Following the first preliminary trial participants were divided into three parallel 
groups, matched based upon the following characteristics; age (years), VO2peak 
absolute (Lmin−1) and relative (mLkg−1min−1), isokinetic maximal voluntary 
contraction strength (MVC) for the eccentric knee flexors (eccKF) (Nm) and the 
concentric knee extensors (conKE) (Nm), body mass (kg) and body fat (%).  
Each group received one of three supplements, consisting of either 4 mgday−1 
astaxanthin (AstaReal®, Sweden) (n = 9), 12 mgday−1 astaxanthin (AstaReal®, 
Sweden) (n = 8) or an appearance-matched placebo with no viable constituents 
(AstaReal®, Sweden) (n = 8). Participants ingested two capsules daily (one morning 




experimental trial had been completed. Compliance was ensured via daily text 
message reminders and a pill count post-ingestion. To ensure the study remained 
double-blind, each supplement was provided with a randomised alphanumerical code 
until after data analysis was complete. 
 
3.2.4.  Experimental Trials 
Following the 8 week supplementation period, and within 7 days of the second 
preliminary trial, participants completed a 30 min downhill run on a motorised 
treadmill (H-P cosmos, Germany). Due to the repeated bout effect synonymous with 
eccentric-type exercise (McHugh, 2003, Proske and Allen, 2005), a familiarisation 
session was not completed. Participants were, however, familiarised with running on 
the motorised treadmill during the GXT, allowing for a degree of familiarity at trial 
onset. On entering the laboratory, a resting venous blood sample was obtained 
alongside pre-exercise measures of perceived muscle soreness and isokinetic MVC. 
After each of these measures were obtained, participants commenced with the 
downhill run. The run lasted for 30 min at a gradient of -12.0%, with speed (kmh−1) 
set to an intensity equivalent to 70% VO2peak (13.3 ± 1.9 kmh
−1). To verify this 
intensity breath-by-breath expired air was collected during the first 10 min of the 
downhill run, with speed altered until 70% VO2peak was consistently achieved. The 
speed at 10 min then remained constant for the remainder of the protocol. Heart rate 
(HR) and RPE (Borg, 1982), for the whole-body (RPEO) and the lower limbs (RPEL) 
were measured at 5 min intervals during the run. Once completed, a post-exercise 




perceived muscle soreness and isokinetic MVC. Each of these measures were 
subsequently obtained 24 h post- and 48 h post-downhill run during two follow-up 
experimental visits. 
 
3.2.5.  Determination of Isokinetic Maximal Voluntary Contraction Strength 
Participants were secured in a seated position on the IKD (Biodex Medical Systems, 
USA) at ~ 90 of hip flexion. Restraints were applied proximal to the knee joint across 
the thigh, waist and chest of each participant. The cuff of the lever arm was secured 
around the ankle, proximal to the malleoli. The lever arm was then aligned with the 
axis of rotation of the knee joint and the anatomical reference was set at 90. Isokinetic 
MVC was then determined for the eccentric knee flexors (eccKF) and concentric knee 
extensors (conKE) of each participant’s dominant lower limb. Prior to data collection 
three familiarisation repetitions were performed at a submaximal intensity. 
Participants then performed one set of three maximal contractions through a full range 
of movement at speeds equivalent to 180s−1 and 60s−1 for both eccKF and conKE. 
Passive knee flexion/extension separated each repetition and a seated rest period of 60 
s interspersed each set. No performance feedback was provided during any of the 
exercise trials. Peak torque (Nm) was identified from each maximal repetition and the 
highest value was used to signify MVC. 
Intraclass correlation coefficient (ICC) analysis has previously been conducted for 
measures of peak torque obtained at speeds equivalent to 180s−1 and 60s−1, for both 
eccKF and conKE, using the same IKD as was used in the current study (Eustace, 




and 60s−1, respectively, with similar values of 0.87 and 0.91 also reported for conKE 
at 180s−1 and 60s−1, indicating almost perfect reliability (Landis and Koch, 1977). 
 
3.2.6.  Perceptions of Muscle Soreness 
Perceptions of muscle soreness were measured using a 100 mm visual analogue scale 
whereby 0 mm indicated “no pain” and 100 mm indicated “unbearable pain” (Close 
et al., 2004). The use of a visual analogue scale has been reported as highly reliable 
for the measurement of acute pain, with an ICC of 0.97 (95% confidence intervals = 
0.96 to 0.98) calculated from 432 paired measures of pain obtained 1 min apart in a 
sample of 96 participants (Bijur, Silver and Gallagher, 2001). It was also reported that 
90% of these values were reproducible within 9 mm, suggesting that a change of > 10 
mm would likely be required to indicate a worthwhile change in pain when using this 
methodological tool (Bijur, Silver and Gallagher, 2001). 
Participants rated perceived muscle soreness following the completion of two 
concentric-eccentric body weight squats. Squat technique was demonstrated and 
familiarised pre-trial. Participants were instructed to rate overall muscle soreness 
before providing individual ratings for localised muscle soreness of the gastrocnemius, 
quadriceps, hamstrings, gluteals and tibialis anterior muscle groups. 
 
3.2.7.  Blood Collection and Analysis 
Blood samples (11 mL) were collected using a 21-gauge needle (BD Vacutainer, 




were collected into either a 6 mL pre-treated vacutainer tube containing 
ethylenediaminetetraacetic acid (EDTA), or a 5 mL pre-treated vacutainer tube 
containing a serum coagulation activator (BD Vacutainer, USA). Prior to 
centrifugation, samples collected for serum analysis were first left to coagulate for 30 
min at room temperature. Samples were then centrifuged at 1000 g for 10 min at 4 C 
(Biofuge Primo R, Sorvall, Thermo Scientific, UK), with the resulting supernatant 
aliquoted and stored at -80 C for subsequent analysis. 
Plasma (EDTA) samples were later used to determine protein carbonyl (PC) 
concentration (nmolmL−1) using a commercially-available colorimetric assay kit 
(Cayman Chemical, USA). In accordance with the manufacturer guidelines, 200 L 
samples were analysed in duplicate utilising a 2,4-dintrophenylhydrazine (DNPH) 
reaction, with the amount of protein-hydrozone produced quantified 
spectrophotometrically at an absorbance of 370 nm (FLUOstar Omega, BMG 
Labtech, Germany). Protein carbonyl concentration (nmolmL−1) for each sample was 
then calculated by inserting the corrected absorbance (CA) into the following 
equation: 
Protein Carbonyl (nmolmL−1) = [(CA)/ (0.011 M−1)] (500 L/200 L) 
Concentrations of C-reactive protein (CRP) (mgL−1), creatine kinase (CK) (UL−1) 
and lactate dehydrogenase (LDH) (UL−1) were also determined in the serum using a 
clinical chemistry analyser (Pentra c400, Horiba, France). Samples of 20 L were 
analysed in duplicate using colorimetry and turbidimetry, with analysis conducted in 
accordance to the manufacturer guidelines. The CVs of each measure are as follows: 




3.2.8.  Statistical Analysis 
Data was first analysed for normality and homogeneity using the Shapiro-Wilk test 
and Levene’s test, respectively. Outliers in the data were also assessed via visual 
inspection of Box Plots, with cases greater than ± 3 SD treated as an outlier in 
subsequent analysis. If an outlier was present (i.e. an outlier was detected in each 
parallel group for measures of serum CRP), statistical analysis was conducted on data 
both with and without said outliers to determine whether this impacted upon the 
outcomes reported (Weisberg, 2014). For the analysis of the primary outcome 
variables (isokinetic MVC, perceptions of muscle soreness, plasma PC and serum CK, 
LDH and CRP) an analysis of covariance (ANCOVA) was conducted with baseline 
scores used as the covariate to determine differences between groups [4 mgday−1 vs. 
12 mgday−1 vs. placebo]. A one-way analysis of variance (ANOVA) was then used 
to determine temporal changes across all groups [pre-exercise vs. immediately post-
exercise vs. 24 h post-exercise vs. 48 h post-exercise] for each primary outcome 
variable. A one-way ANOVA was also used to compare group differences [4 mgday−1 
vs. 12 mgday−1 vs. placebo] in exercise intensity [VO2 and running speed] during the 
30 min downhill run, as well as baseline measures of age, VO2peak, isokinetic MVC 
for eccKF and conKE, body mass and body fat to determine whether each parallel 
group was successfully matched. A two-way group [4 mgday−1 vs. 12 mgday−1 vs. 
placebo] x time [5, 10, 15, 20, 25, 30] ANOVA was then conducted to determine 
differences in RPEO, RPEL and HR obtained during the downhill run. If a significant 
main effect or interaction was observed, post-hoc analysis was performed with a 




classified as trivial (< 0.01), small (0.01-0.059) moderate (0.06-0.137) or large (≥ 
0.138) (Cohen, 1988). Confidence intervals (± 95%) were also calculated and are 
reported where necessary. Descriptive data are displayed as mean ± SD unless 
otherwise stated. Statistical analysis for all data was conducted using a statistical 
software package (SPSS, Version 25, USA), with significance accepted at p < 0.05. 
 
3.3. Results  
3.3.1.  Isokinetic Maximal Voluntary Contraction Strength 
At a movement speed of 180s−1 the decrease in eccKF MVC was not influenced by 
astaxanthin supplementation immediately post-exercise (4 mgday−1: 138.0 ± 13.9 
Nm vs. 12 mgday−1: 133.5 ± 13.9 Nm vs. placebo: 135.7 ± 14.2 Nm; p = 0.798, P2 
= 0.021), 24 h post-exercise (4 mgday−1: 134.6 ± 20.0 Nm vs. 12 mgday−1: 126.9 ± 
20.3 Nm vs. placebo: 124.9 ± 19.9 Nm; p = 0.582, P2 = 0.050), or 48 h post-exercise 
(4 mgday−1: 131.7 ± 22.5 Nm vs. 12 mgday−1: 132.8 ± 22.4 Nm vs. placebo: 129.8 
± 22.9 Nm; p = 0.966, P2 = 0.003) (Figure 3.1a). This was similar for measures of 
eccKF MVC obtained at 60s−1, with no effect of astaxanthin reported immediately 
post-exercise (4 mgday−1: 129.8 ± 12.3 Nm vs. 12 mgday−1: 121.5 ± 12.2 Nm vs. 
placebo: 132.9 ± 12.3 Nm; p = 0.180, P2 = 0.151), 24 h post-exercise (4 mgday−1: 
131.1 ± 20.0 Nm vs. 12 mgday−1: 127.2 ± 19.9 Nm vs. placebo: 115.6 ± 20.1 Nm; 
p = 0.286, P2 = 0.112) or 48 h post-exercise (4 mgday−1: 128.9 ± 20.5 Nm vs. 12 





At a movement speed of 180s−1 the decrease in conKE MVC was also not influenced 
by astaxanthin supplementation immediately post-exercise (4 mgday−1: 162.8 ± 16.5 
Nm vs. 12 mgday−1: 162.6 ± 16.1 Nm vs. placebo: 165.0 ± 16.4 Nm; p = 0.950, P2 
= 0.005), 24 h post-exercise (4 mgday−1: 167.1 ± 16.8 Nm vs. 12 mgday−1: 161.3 ± 
16.5 Nm vs. placebo: 155.5 ± 16.7 Nm; p = 0.414, P2 = 0.085), or 48 h post-exercise 
(4 mgday−1: 170.3 ± 19.9 Nm vs. 12 mgday−1: 156.9 ± 19.5 Nm vs. placebo: 157.7 
± 19.8 Nm; p = 0.345, P2 = 0.101) (Figure 3.1c). This was similar for measures of 
conKE MVC obtained at 60s−1, with no effect of astaxanthin reported immediately 
post-exercise (4 mgday−1: 210.0 ± 19.8 Nm vs. 12 mgday−1: 199.7 ± 19.8 Nm vs. 
placebo: 201.7 ± 19.6 Nm; p = 0.557, P2 = 0.057), 24 h post-exercise (4 mgday−1: 
213.5 ± 22.3 Nm vs. 12 mgday−1: 194.0 ± 22.3 Nm vs. placebo: 187.5 ± 22.1 Nm; 
p = 0.076, P2 = 0.228) or 48 h post-exercise (4 mgday−1: 218.5 ± 32.6 Nm vs. 12 
mgday−1: 202.8 ± 32.7 Nm vs. placebo: 196.7 ± 32.4 Nm; p = 0.401, P2 = 0.087) 
(Figure 3.1d). 
 
3.3.2.  Perceptions of Muscle Soreness 
There was no effect of astaxanthin supplementation reported for perceptions of overall 
muscle soreness immediately post-exercise (4 mgday−1: 45 ± 23 AU vs. 12 mgday−1: 
45 ± 23 AU vs. placebo: 54 ± 23 AU; p = 0.701, P2 = 0.033), 24 h post-exercise (4 
mgday−1: 59 ± 24 AU vs. 12 mgday−1: 49 ± 24 AU vs. placebo: 58 ± 24 AU; p = 
0.667, P2 = 0.038) or 48 h post-exercise (4 mgday−1: 47 ± 24 AU vs. 12 mgday−1: 




similar for perceptions of localised muscle soreness, with astaxanthin supplementation 
not influencing measures obtained immediately post-exercise (4 mgday−1: 37 ± 17 
AU vs. 12 mgday−1: 34 ± 17 AU vs. placebo: 35 ± 17 AU; p = 0.949, P2 = 0.005), 
24 h post-exercise (4 mgday−1: 42 ± 17 AU vs. 12 mgday−1: 34 ± 17 AU vs. placebo: 
34 ± 17 AU; p = 0.525, P2 = 0.059) or 48 h post-exercise (4 mgday−1: 39 ± 17 AU 
vs. 12 mgday−1: 27 ± 17 AU vs. placebo: 35 ± 17 AU; p = 0.362, P2 = 0.092) (Figure 
3.2b). 
 
3.3.3.  Biomarkers of Oxidative Stress and Inflammation 
There was no effect of astaxanthin supplementation on the increase in plasma PC 
observed immediately post-exercise (4 mgday−1: 35.85 ± 7.33 nmolmL−1 vs. 12 
mgday−1: 33.14 ± 7.27 nmolmL−1 vs. placebo: 42.29 ± 7.53 nmolmL−1; p = 0.077, 
P2 = 0.226), 24 h post-exercise (4 mgday−1: 35.04 ± 7.52 nmolmL−1  vs. 12 
mgday−1: 34.20 ± 7.46 nmolmL−1 vs. placebo: 36.71 ± 7.73 nmolmL−1; p = 0.817, 
P2 = 0.020) or 48 h post-exercise (4 mgday−1: 32.28 ± 6.52 nmolmL−1 vs. 12 
mgday−1: 30.18 ± 6.47 nmolmL−1 vs. placebo: 34.59 ± 6.70 nmolmL−1; p = 0.459, 
P2 = 0.075) (Figure 3.3a). 
Concentrations of serum CRP were also unaffected by astaxanthin supplementation, 
with or without the presence of outliers, with no differences between groups reported 
immediately post-exercise (with outliers: 4 mgday−1: 0.23 ± 0.05 mgL−1 vs. 12 
mgday−1: 0.24 ± 0.05 mgL−1 vs. placebo: 0.24 ± 0.05 mgL−1; p = 0.851, P2 = 0.015; 




vs. placebo: 0.21 ± 0.05 mgL−1; p = 0.979, P2 = 0.002), 24 h post-exercise (with 
outliers: 4 mgday−1: 0.95 ± 0.62 mgL−1 vs. 12 mgday−1: 0.80 ± 0.62 mgL−1 vs. 
placebo: 0.75 ± 0.62 mgL−1; p = 0.780, P2 = 0.023; without outliers: 4 mgday−1: 
0.68 ± 0.39 mgL−1  vs. 12 mgday−1: 0.61 ± 0.40 mgL−1 vs. placebo: 0.76 ± 0.40 
mgL−1; p = 0.786, P2 = 0.026) or 48 h post-exercise (with outliers: 4 mgday−1: 0.60 
± 0.64 mgL−1 vs. 12 mgday−1: 0.72 ± 0.64 mgL−1 vs. placebo: 0.49 ± 0.64 mgL−1; p 
= 0.780, P2 = 0.023; without outliers: 4 mgday−1: 0.39 ± 0.25 mgL−1 vs. 12 
mgday−1: 0.41 ± 0.25 mgL−1 vs. placebo: 0.51 ± 0.25 mgL−1; p = 0.612, P2 = 0.053) 
(Figure 3.3b). 
 
3.3.4.  Biomarkers of Muscle Damage 
Astaxanthin supplementation did not attenuate the increase in serum CK reported 
immediately post-exercise (4 mgday−1: 202 ± 58 UL−1 vs. 12 mgday−1: 207 ± 60 
UL−1 vs. placebo: 221 ± 59 UL−1; p = 0.790, P2 = 0.022), 24 h post-exercise (4 
mgday−1: 720 ± 371 UL−1  vs. 12 mgday−1: 643 ± 387 UL−1 vs. placebo: 761 ± 378 
UL−1; p = 0.834, P2 = 0.017) or 48 h post-exercise (4 mgday−1: 425 ± 243 UL−1 vs. 
12 mgday−1: 329 ± 254 UL−1 vs. placebo: 414 ± 248 UL−1; p = 0.660, P2 = 0.041) 
(Figure 3.4a). 
Similarly, astaxanthin supplementation did not attenuate the increase in serum LDH 
reported immediately post-exercise (4 mgday−1: 423 ± 33 UL−1 vs. 12 mgday−1: 427 
± 34 UL−1 vs. placebo: 412 ± 33 UL−1; p = 0.615, P2 = 0.045), 24 h post-exercise 




UL−1; p = 0.642, P2 = 0.041) or 48 h post-exercise (4 mgday−1: 377 ± 42 UL−1 vs. 
12 mgday−1: 387 ± 42 UL−1 vs. placebo: 389 ± 42 UL−1; p = 0.805, P2 = 0.020) 
(Figure 3.4b). 
 
3.3.5. Temporal Responses 
There was a temporal response reported across all groups for post-exercise changes in 
isokinetic MVC (p < 0.003, P2 > 0.174), perceptions of muscle soreness (p < 0.001, 
P2 > 0.620), plasma PC (p < 0.001, P2 = 0.248) and serum CRP (p < 0.001, P2 = 
0.382), CK (p < 0.001, P2 = 0.686) and LDH (p < 0.001, P2 = 0.547). As such, the 
use of a downhill run to induce significant levels of muscle damage in this study was 
deemed a success. Each of these temporal responses are signified by (#) in Figures 
3.1-3.4 below. 
 
3.3.6.  Heart Rate, RPEO and RPEL 
A main effect of time was present for HR (p < 0.001, P = 0.786), RPEO (p < 0.001, 
P = 0.727) and RPEL (p < 0.001, P
2 = 0.667) with each variable progressively 
increasing throughout the 30 min downhill run. No [group x time] interactions (p > 
0.926, P < 0.040) or main effects of group (p > 0.606, P2 < 0.044) were reported 





3.3.7.  Group Matching 
Experimental groups were deemed as being successfully matched, with no significant 
differences reported between groups for downhill running speed or intensity (p > 
0.486, P < 0.063) or any of the baseline characteristics provided in Table 3.1 (p > 






Figure 3.1 Unadjusted mean ± SD. Absolute differences in isokinetic maximal 
voluntary contraction strength (MVC) when compared to values obtained pre-exercise 
for the eccentric knee flexors (eccKF) at movement speeds of 180s−1 (a) and 60s−1 
(b) and the concentric knee extensors (conKE) at movement speeds of 180s−1 (c) and 
60s−1 (d). IP = immediately post-exercise, 24 = 24 h post-exercise and 48 = 48 h 





Figure 3.2 Unadjusted mean ± SD. Absolute differences in overall muscle soreness 
(a) and localised muscle soreness (b) when compared to values obtained pre-exercise. 
IP = immediately post-exercise, 24 = 24 h post-exercise and 48 = 48 h post-exercise, 






Figure 3.3 Unadjusted mean ± SD. Absolute differences in concentrations of protein 
carbonyls (PC) (a) and C-reactive protein (CRP) (b) when compared to values 
obtained pre-exercise. IP = immediately post-exercise, 24 = 24 h post-exercise and 48 







Figure 3.4 Unadjusted mean ± SD. Absolute differences in concentrations of creatine 
kinase (CK) (a) and lactate dehydrogenase (LDH) (b) when compared to values 
obtained pre-exercise. IP = immediately post-exercise, 24 = 24 h post-exercise and 48 







Figure 3.5 Mean ± SD. Heart rate (a) and ratings of perceived exertion for the whole-
body (RPEO) and the lower limbs (RPEL) obtained over the duration of the 30 min 




Table 3.1 Mean ± SD. Participant characteristics used for group matching at baseline 
and for the speed and intensity the downhill run was completed at.  
Variable 4 mgday−1 12 mgday−1 Placebo 
Age (years) 25 ± 3 25 ± 4 28 ± 6 
Body mass (kg) 80.5 ± 9.7 82.7 ± 9.6 81.5 ± 6.2 
Body fat (%) 15.8 ± 5.3 16.8 ± 4.3 17.0 ± 2.2 
VO2peak (Lmin−1) 4.06 ± 0.40 4.11 ± 0.52 3.97 ± 0.43 
VO2peak (mLkg−1min−1) 50.9 ± 6.9 49.9 ± 5.5 48.8 ± 4.9 
EccKF MVC at 180s−1 (Nm) 153.4 ± 29.7 154.5 ± 20.0 167.6 ± 25.2 
EccKF MVC at 60s−1 (Nm) 144.0 ± 25.6 147.4 ± 19.6 153.0 ± 23.5 
ConKE MVC at 180s−1 (Nm) 164.5 ± 31.6 172.9 ± 29.8 180.9 ± 25.7 
ConKE MVC at 60s−1 (Nm) 220.1 ± 45.1 238.8 ± 44.0 228.0 ± 50.8 
Downhill Running Speed (kmh−1) 13.6 ± 1.6 13.4 ± 2.6 13.0 ± 1.5 
Downhill Running Intensity (% VO2peak) 69.3 ± 2.2 70.2 ± 1.2 70.4 ± 2.3 
    
    





The current investigation was conducted to explore the effect of astaxanthin 
supplementation on the muscle damage response to a 30 min downhill run in 
recreationally active males. In comparison to placebo, prior supplementation with 4 
mgday−1 or 12 mgday−1 astaxanthin for 8 weeks did not attenuate the post-exercise 
increase in muscle damage and did not accelerate the recovery process in the 48 h 
post-exercise when compared to the placebo. 
The findings of the current study are similar to those reported in resistance trained 
males following the completion of 10 sets of 10 eccentric knee extensions at 85% one 
repetition maximum (Bloomer et al., 2005). Resistance trained males were recruited 
to this study due to being a population that regularly trains with the volume and 
intensity required to induce muscle damage and potentially benefit from astaxanthin 
supplementation. Three weeks of 4 mgday−1 astaxanthin supplementation, however, 
did not exert an effect on indices of muscle soreness, CK and the recovery of isokinetic 
and isometric MVC in the 92 h post-exercise when compared to the placebo (Bloomer 
et al., 2005). As resistance trained individuals were recruited, it was purported that the 
potential for astaxanthin to exert a recovery benefit may have been confounded by the 
repeated bout effect, whereby the protective adaptations induced by regular adherence 
to muscle damaging exercise would have reduced the muscle damage responses 
observed in this study (Proske and Allen, 2005). The current study, however, reports 
a similar outcome in recreationally active males unaccustomed to eccentric exercise 
and high-force resistance training, suggesting that training status does not confound 




supplementation with 4 mgday−1 and 12 mgday−1 astaxanthin for 8 weeks did not 
exert an effect on similar measures of muscle soreness, CK and isokinetic MVC in the 
48 h following a downhill run when compared to the placebo. 
The findings of the current study are also similar to those reported in elite youth male 
soccer players following the completion of a 2 h bout of soccer exercise (n = 32; age: 
17–18 years) (Djordjevic et al., 2012). A supplement effect of 4 mgday−1 astaxanthin 
for 90 days, for example, was not reported in exercise-induced changes in plasma CK 
and generic measures of oxidative stress (TBARS, advanced oxidation protein 
products, superoxide anion, total antioxidant status, sulphydril groups, and SOD), 
suggesting a recovery effect was not present (Djordjevic et al., 2012). A similar study 
was later conducted in a separate cohort of elite youth male soccer players  (n = 40; 
age: 17–18 years) (Baralic et al., 2015). In comparison to the exercising control, 4 
mgday−1 astaxanthin for 90 days was suggested to augment the training-induced 
reductions in both plasma CK (astaxanthin: −44.6%; control: −30.1%) and LDH 
(astaxanthin: −27.4%; control: −18.5%), while also attenuating training-induced 
increases in markers of inflammation, such as serum CRP and total leukocyte and 
neutrophil counts (Baralic et al., 2015). Caution is required however, as a significant 
supplement effect of astaxanthin was not reported in regard to each of the 
aforementioned measures, apart from the LDH biomarker (p < 0.05); suggesting that 
astaxanthin actually had little effect. Together these studies seemingly question the 
recovery potential of astaxanthin following the completion of muscle damaging 




When completing a bout of eccentric exercise, the initial muscle damage response is 
thought to be caused by the significant mechanical stress inflicted upon the exercising 
skeletal muscle and the concomitant increase in oxidative stress that results from this 
(Proske and Allen, 2005, Bowtell et al., 2011). This initial increase in oxidative stress 
and muscle injury is then thought to trigger a secondary inflammatory response which 
is thought to delay the recovery process and contribute to DOMS (Close et al., 2004, 
Mcleay et al., 2012). In the current study, measures of PC, CRP, CK and LDH were 
used as biomarkers of the oxidative stress, inflammatory and muscle damage 
responses to exercise. Indeed, increases in each of these biomarkers are commonly 
reported in response to exercise-induced muscle damage (Bloomer et al., 2007, 
Bowtell et al., 2011, Mcleay et al., 2012), a temporal response which was also 
observed in the current study (Figures 3.3 and 3.4). As astaxanthin did not provide a 
protective benefit to any of these biomarkers, with no differences reported between 
groups at any time point, the ability for astaxanthin to attenuate the initial and 
secondary phases of muscle damage are seemingly questioned. This outcome may also 
explain why astaxanthin did not attenuate the immediate and delayed changes in 
isokinetic MVC and perceptions of muscle soreness obtained at the same time points 
in the current study. 
In sport nutrition and exercise physiology research, eccentric exercise protocols have 
received widespread use when aiming to quantify the recovery benefits of a particular 
intervention (Close et al., 2006, Bowtell et al., 2011, Mcleay et al., 2012, Hutchison 
et al., 2016). As the repeated bout effect is well-documented, however, parallel group 
designs are often relied upon, especially when whole-body exercise protocols are 




upon baseline characteristics as described in 3.2.3. Group Matching. Despite no 
between group differences being observed statistically, with subtle differences also 
controlled using an ANCOVA, the response of bloodborne biomarkers and 
perceptions of muscle soreness to eccentric exercise are known to vary considerably 
between individuals (Bloomer et al., 2005, Bowtell et al., 2011). 
To overcome this, single-limb muscle damaging exercise has been used as an 
alternative experimental design to mitigate the inter-individual variability often 
reported for exercise-induced muscle damage (Connolly et al., 2006, Bowtell et al., 
2011). Experimental trials are counterbalanced for supplement and leg dominance to 
avoid a potential order effect, with the repeated bout effect reported as much smaller 
in the contralateral limb and to not confound the muscle damage responses observed 
in the 48 h following a second experimental trial (Howatson and van Someren, 2007, 
Bowtell et al., 2011). Future investigations into the recovery potential of astaxanthin 
should, therefore, consider utilising a single-limb experimental protocol so that a 
randomised crossover design can be employed. In doing so, each participant can act 
as their own control, minimising the confounding influence inter-individual variances 
in muscle damage could have upon outcome variables. 
In conclusion, prior supplementation with 4 mgday−1 or 12 mgday−1 astaxanthin for 
8 weeks did not provide a protection against exercise-induced muscle damage or 
accelerate the recovery process in recreationally active males following the 
completion of a 30 min downhill run. The uptake of astaxanthin was assumed, 
however, and not verified in the current investigation. Future research should seek to 




experimental protocol that enables the use of a randomised crossover design so that 








4. The Effect of Two Doses of Astaxanthin Supplementation on the 









Increases in the fat oxidative capacity are often associated with numerous benefits 
pertaining to endurance performance and overall health (Fletcher et al., 2017). As 
such, methods capable of improving the fat oxidative capacity, both at rest and during 
exercise, continue to receive a plethora of research attention in sport, exercise and 
health nutrition (Hawley, Brouns and Jeukendrup, 1998, Yeo et al., 2011, Burke, 2015, 
Robinson et al., 2015, Fletcher et al., 2017). One potential method that has been 
investigated using a mice experimental model is astaxanthin supplementation. Indeed, 
evidence derived from mice would suggest that supplementation with astaxanthin for 
3-5 weeks can increase the fat oxidative capacity during the completion of endurance 
exercise (Ikeuchi et al., 2006, Aoi et al., 2008). This is attributed to the potential for 
astaxanthin to protect the mitochondria from oxidative modifications induced by 
RONS during exercise, enabling an enhanced intercalation between FAT/CD36 and 
CPT1 on the mitochondrial membrane (Aoi et al., 2008). 
In humans, however, a similar metabolic effect has yet to be replicated, with 4 weeks 
of astaxanthin supplementation (4 mgday−1 and 20 mgday−1) not influencing 
parameters of substrate metabolism (such as RER, carbohydrate and fat oxidation 
rates, and plasma glucose and NEFA concentrations) during 1-2 h of constant-load 
submaximal exercise in trained male individuals (Earnest et al., 2011, Res et al., 2013). 
It should be noted, that the rate at which fat is oxidised during exercise, and the 
exercise intensity at which this is maximal (FATmax), is subject to large variation 
between individuals (Goedecke et al., 2000, Venables, Achten and Jeukendrup, 2005). 




77% VO2max were reported despite an average value of 48 ± 1% VO2max reported 
overall (Venables, Achten and Jeukendrup, 2005). Consequently, the ability for 
previous research (Earnest et al., 2011, Res et al., 2013) to uncover a potential 
metabolic effect of astaxanthin during constant-load submaximal exercise may have 
been constrained by some individuals exercising above and others below the intensity 
at which MFO is elicited. For this reason, the current study utilises a FATmax protocol 
so that potential changes in whole-body fat oxidation can be determined over a wide 
range of exercise intensities throughout supplementation (Achten, Gleeson and 
Jeukendrup, 2002).  
Res et al. (2013) also detected no measurable changes in the plasma concentrations of 
the lipid peroxide malondialdehyde (MDA) during exercise, suggesting an antioxidant 
effect of astaxanthin was not present. Although speculative, this observation may 
provide a further insight as to why a metabolic effect was not reported in this study, 
with previous research suggesting an indirect metabolic modulation is mediated 
through the potent antioxidant function of astaxanthin within the mitochondrial 
membrane (Aoi et al., 2008). Concentrations of MDA are, however, reported to 
decrease significantly in individuals supplementing with 20 mgday−1 astaxanthin for 
both 8 and 12 weeks, respectively (Choi, Youn and Shin, 2011). Likewise, 12 weeks 
of 8 mgday−1 astaxanthin supplementation also attenuated markers of lipid 
peroxidation in healthy males (Karppi et al., 2007), potentially suggesting that a 
supplementation period of > 8 weeks may be necessary to elicit the metabolic potential 
of astaxanthin in a human cohort. As such, the current study implements both a 4 week 




term supplementation with astaxanthin (4 mgday−1 and 12 mgday−1) can increase the 




4.2.1.  Participants 
Thirty recreationally active males (age: 25 ± 5 years, height 1.78 ± 0.07 m, body mass 
81.0 ± 9.6 kg, body fat 16.4 ± 3.8%) provided written informed consent and 
participated in the study. Participants were not permitted to supplement with 
additional antioxidants/vitamins alongside those provided in the current study. A list 
of commonly consumed astaxanthin-rich foods to avoid was also provided to limit the 
additional dietary intake of astaxanthin during supplementation. Participants were also 
instructed to refrain from strenuous exercise and the consumption of alcohol and 
caffeine in the 24 h preceding each visit (Rosenberg et al., 1978, Westerterp-Plantenga 
et al., 2006), and to enter the laboratory following an overnight fast (~ 10 h), with the 
exception of ingesting water to ensure euhydration. Compliance with the above 
procedures was checked via 24 h dietary recall, with participants asked to replicate 
dietary intake prior to each trial. All participants visited the laboratory at a similar time 
of day (± 1 h) on seven separate occasions (one preliminary trial and six experimental 





4.2.2.  Preliminary Trial 
All participants were familiarised with all testing equipment and procedures to be used 
to minimise both learning and anxiety effects. This involved the performance of a 
FATmax protocol identical to those performed during each experimental trial. A 
description of this protocol is provided in section 4.2.3. Experimental Trials. 
 
4.2.3.  Experimental Trials 
On entering the laboratory measures of height and body mass were obtained, with 
body composition also determined using air displacement plethysmography. 
Participants then completed a FATmax protocol to volitional exhaustion on a motorised 
treadmill. Adapted from previously described and validated protocols (Achten, 
Venables and Jeukendrup, 2003, Fletcher et al., 2017, Randell et al., 2017), exercise 
commenced at a speed of 3.5 kmh−1 and a gradient of 1.0%. Speed was then increased 
by 1.0 kmh−1 every 3 min until a RER of 1.00 was reached, indicating that fat 
oxidation had become negligible (FATmin) (Jeukendrup and Wallis, 2005). To enable 
the determination of VO2peak, speed then remained constant and the gradient was 
increased by 1.0% every min until a 3.0% gradient was achieved. The gradient was 
then kept constant and the speed was increased by 1.0 kmh−1 until volitional 
exhaustion. Breath-by-breath expired air was collected for VO2peak determination and 
was defined as the highest 30 s average of VO2 recorded during the FATmax protocol. 
Heart rate and RPE (Borg, 1982) were also collected throughout exercise. Participants 
completed the FATmax protocol on two separate occasions at baseline, 4 weeks (± 2 




with the average of the two measurements taken at each time point. Each trial was 
separated by > 48 h. 
During analysis, substrate utilisation rates were calculated using the VO2 and VCO2 
data obtained during the final 60 s of each 3 min submaximal stage. The stoichiometric 
equations proposed by Jeukendrup and Wallis (2005) were used, assuming protein 
oxidation during exercise is negligible. Calculated fat oxidation rates were then plotted 
as a function of exercise intensity (% VO2peak and % HRmax) and a 3
rd degree 
polynomial curve with intersection at (0;0) was constructed for each participant 
(Stisen et al., 2006, Croci et al., 2014). Values for FATmax (% VO2peak and % HRmax), 
FATmin (% VO2peak and % HRmax), MFO (gmin
−1) and MFO relative to fat free mass 
(MFOFFM) (mgkg FFM
−1min−1) were then determined, with the FATzone also 
calculated as the range of exercise intensities within 10% of MFO (Achten, Gleeson 
and Jeukendrup, 2002). To enable further comparisons, the lower and higher limits of 
the FATzone were calculated and are referred to as “FATzone low” and “FATzone high” 
(% VO2peak and % HRmax) (Achten, Gleeson and Jeukendrup, 2002). The area under 
the curve (AUC) for total fat oxidised (g) was also calculated using the trapezoid 
method for both the FATzone (FATzone AUC) and the submaximal portion of the 
FATmax protocol (submax AUC). The submaximal portion consisted of each 3 min 
stage of the FATmax protocol completed prior to a RER of 1.00 being achieved. 
 
4.2.4.  Group Matching 
Following the second baseline trial, participants were divided into three parallel 




absolute (Lmin−1) and relative (mLkg−1 min−1), FATmax (% VO2peak and % HRmax), 
MFO (gmin−1 and mgkg FFM−1min−1), body mass (kg) and body fat (%). Each group 
received one of three supplements, consisting of either 4 mgday−1 astaxanthin 
(AstaReal®, Sweden), 12 mgday−1 astaxanthin (AstaReal®, Sweden) or an 
appearance-matched placebo with no viable constituents (AstaReal®, Sweden). 
Participants ingested two capsules daily (one morning and one evening) for the 
entirety of the 8 week protocol, with compliance ensured via daily text message 
reminders and a pill count post-ingestion. To ensure the study remained double-blind, 
each supplement was provided with a randomised alphanumerical code until after data 
analysis was complete. 
 
4.2.5.  Statistical Analysis 
Data was first analysed for normality using the Shapiro-Wilk test and standard 
graphical methods (Box Plots), and for homogeneity using the Levene’s test. For the 
analysis of the primary outcome variables (FATmax, MFO, FATzone, FATmin and AUC) 
an ANCOVA was conducted with baseline scores used as the covariate to determine 
differences between groups [4 mgday−1 vs. 12 mgday−1 vs. placebo] after 4 weeks 
and 8 weeks of supplementation. To determine whether each parallel group was 
successfully matched, between group [4 mgday−1 vs. 12 mgday−1 vs. placebo] 
differences in baseline measures of age, VO2peak, FATmax, MFO, body mass and body 
fat were analysed using a one-way ANOVA. A two-way group [4 mgday−1 vs. 12 
mgday−1 vs. placebo] x time [baseline and 8 weeks] ANOVA was also conducted to 




body fat) during the 8 week supplementation period and whether inferred changes 
were different between groups. If a significant main effect or interaction was observed, 
post-hoc analysis was performed with a Bonferroni adjustment. Effect sizes (P2) 
were calculated and classified as trivial (< 0.01), small (0.01-0.059) moderate (0.06-
0.137) or large (≥ 0.138) (Cohen, 1988). Confidence intervals (± 95%) were also 
calculated and are reported where necessary. Descriptive data are displayed as mean 
± SD unless otherwise stated. Statistical analysis for all data was conducted using a 




4.3.1.  FATmax and FATmin 
Astaxanthin supplementation did not exert an effect on the exercise intensity (% 
VO2peak or % HRpeak) at which fat oxidation was reported to be maximal (FATmax), 
with no significant differences reported between groups following  4 weeks (VO2: p = 
0.973, P2 = 0.002; HR: p = 0.617, P2 = 0.037) and 8 weeks (VO2: p = 0.939, P
2 = 
0.005,  HR: p = 0.431, P2 = 0.063) of supplementation (Table 4.1). Similarly, the 
exercise intensity (% VO2peak or % HRpeak) at which fat oxidation became negligible 
(FATmin) was not significantly different between groups following 4 weeks (VO2: p = 
0.442, P2 = 0.061; HR: p = 0.718, P2 = 0.025) and 8 weeks (VO2: p = 0.270, P
2 = 





4.3.2.  Maximal Fat Oxidation Rates 
There was no effect of astaxanthin supplementation on MFO (gmin−1), calculated as 
both a function of VO2 and HR, with no significant differences reported between 
groups following 4 weeks (VO2: p = 0.826, P
2 = 0.015; HR: p = 0.909, P2 = 0.007) 
and 8 weeks (VO2: p = 0.987, P
2 = 0.001; HR: p = 0.844, P2 = 0.013) of 
supplementation (Table 4.2). There were also no significant differences reported 
between groups for measures of  MFOFFM (mgkg FFM
−1min−1) obtained following 4 
weeks (VO2: p = 0.870, P
2 = 0.011; HR: p = 0.923, P2 = 0.006) and 8 weeks (VO2: 
p = 0.956, P2 = 0.003; HR: p = 0.809, P2 = 0.016) of astaxanthin supplementation 
(Table 4.2). 
 
4.3.3.  Area Under the Curve 
There were no differences reported between groups for calculations of submax AUC 
(g) following 4 weeks (VO2: p = 0.679, P
2 = 0.029; HR: p = 0.868, P2 = 0.011) and 
8 weeks (VO2: p = 0.962, P
2 = 0.003; HR: p = 0.994, P2 < 0.001) of astaxanthin 
supplementation (Table 4.3). Area under the curve calculations for total fat oxidised 
(g) within the FATzone (FATzone AUC) were also not significantly different between 
groups following 4 weeks (VO2: p = 0.732, P
2 = 0.024; HR: p = 0.550, P2 = 0.045) 
and 8 weeks (VO2: p = 0.987, P
2 = 0.001; HR: p= 0.904, P2 = 0.008) of astaxanthin 
supplementation (Table 4.3).  
A similar outcome is reported for the lower and higher limits of the FATzone (% VO2peak 




groups after 4 weeks (VO2: p = 0.913, P
2 = 0.007; HR: p = 0.784, P2 = 0.019) and 
8 weeks (VO2: p = 0.947, P
2 = 0.004; HR: p = 0.682, P2 = 0.029) of astaxanthin 
supplementation, with values for FATzone high also unchanged between groups at the 
same time points (4 weeks: VO2: p = 0.896, P
2 = 0.008; HR: p = 0.537, P2 = 0.047; 
8 weeks: VO2: p = 0.884, P
2 = 0.009; HR: p = 0.303, P2 = 0.088) (Table 4.3). 
 
4.3.4.  Baseline Group Matching 
There were no significant differences reported between groups for any of the baseline 
characteristics provided in Table 4.4 (p > 0.682, P2 < 0.028). As such, baseline group 
matching was deemed successful. 
 
4.3.5.  Changes in Training Status 
Participants were able to successfully maintain their training status over the 8 week 
supplementation period. This is inferred by there being no main effect of time (p > 
0.437, P2 < 0.023), group (p > 0.595, P2 < 0.038) or a [time x group] interaction (p 
> 0.436, P2 < 0.060) for measures of VO2peak (Lmin
−1 and mLkg−1 min−1), body 
mass (kg) and body fat (%) obtained at baseline and 8 weeks, respectively (Table 4.5). 
 
4.3.6.  Coefficient of Variation Calculations 








Table 4.1 Mean ± SD. Adjusted values of FATmax (% VO2peak and % HRmax) and FATmin (% VO2peak and % HRmax) obtained following 4 
weeks and 8 weeks of supplementation with either 4 mgday−1 astaxanthin, 12 mgday−1 astaxanthin or a placebo. “Difference” denotes 
the mean difference (± 95% CI) when compared to placebo. Baseline values for each variable were used as the covariate. 
Variable Week 4 Week 8 
 4 mgday−1 12 mgday−1 Placebo 4 mgday−1 12 mgday−1 Placebo 
FATmax       
VO2 47.8 ± 4.3 47.5 ± 4.3 47.4 ± 4.3 47.7 ± 3.8 47.4 ± 3.8 47.1 ± 3.8 
Difference +0.4 (-5.4 to 5.0) +0.1 (-4.9 to 5.0)  +0.3 (-4.1 to 4.7) +0.6 (-3.8 to 4.9)  
HR 59.9 ± 4.7 57.9 ± 4.7 58.7 ± 4.6 60.6 ± 4.9 57.8 ± 4.9 59.7 ± 4.9 
Difference +1.1 (-4.1 to 6.5) -0.9 (-6.2 to 4.5)  +0.9 (-4.7 to 6.5) -1.9 (-7.5 to 3.7)  
FATmin       
VO2 86.9 ± 4.5 84.4 ± 4.6 86.4 ± 4.6 86.9 ± 5.4 83.7 ± 5.5 87.5 ± 5.5 
Difference +0.5 (-4.7 to 5.7) -2.0 (-7.3 to 3.3)  +0.6 (-5.7 to 6.9) -3.8 (-10.2 to 2.6)  
HR 92.4 ± 4.5 90.9 ± 4.5 91.2 ± 4.6 92.5 ± 4.7 90.9 ± 4.7 93.5 ± 4.7 







Table 4.2 Mean ± SD. Adjusted values of MFO (gmin−1) and MFOFFM (mgkg FFM
−1min−1) obtained following 4 weeks and 8 weeks 
of supplementation with either 4 mgday−1 astaxanthin, 12 mgday−1 astaxanthin or a placebo. “Difference” denotes the mean difference 
(± 95% CI) when compared to placebo. Baseline values for each variable were used as the covariate. 
Variable Week 4 Week 8 
 4 mgday−1 12 mgday−1 Placebo 4 mgday−1 12 mgday−1 Placebo 
MFO       
VO2 0.49 ± 0.07 0.48 ± 0.07 0.48 ± 0.07 0.46 ± 0.10 0.47 ± 0.10 0.46 ± 0.10 
Difference +0.02 (-0.07 to 0.10) +0.00 (-0.08 to 0.09)  -0.01 (-0.12 to 0.11) +0.00 (-0.11 to 0.12)  
HR 0.49 ± 0.07 0.47 ± 0.07 0.48 ± 0.07 0.45 ± 0.11 0.47 ± 0.11 0.46 ± 0.11 
Difference +0.01 (-0.08 to 0.09) -0.01 (-0.09 to 0.07)  -0.02 (-0.14 to 0.11) +0.01 (-0.12 to 0.13)  
MFOFFM       
VO2 7.23 ± 1.03 7.08 ± 1.03 7.00 ± 1.03 6.74 ± 1.45 6.92 ± 1.45 6.79 ± 1.45 
Difference +0.24 (-0.94 to 1.42) +0.08 (-1.01 to 1.33)  -0.06 (-1.72 to 1.60) +0.12 (-1.53 to 1.78)  
HR 7.14 ± 1.03 6.95 ± 1.03 7.06 ± 1.03 6.53 ± 1.53 6.97 ± 1.53 6.83 ± 1.53 







Table 4.3 Mean ± SD. Adjusted values of submax AUC (g), FATzone AUC (g), FATzone low (% VO2peak or % HRmax) and FATzone high (% 
VO2peak or % HRmax) obtained following 4 weeks and 8 weeks of supplementation with either 4 mgday
−1 astaxanthin, 12 mgday−1 
astaxanthin or a placebo. “Difference” denotes the mean difference (± 95% CI) when compared to placebo. Baseline values for each 
variable were used as the covariate. 
Variable Week 4 Week 8 
 4 mgday−1 12 mgday−1 Placebo 4 mgday−1 12 mgday−1 Placebo 
Submax AUC       
VO2 23.05 ± 4.52 21.76 ± 4.52 21.32 ± 4.52 21.40 ± 5.82 20.82 ± 5.82 20.73 ± 5.82 
Difference +1.73 (-3.45 to 6.90) +0.44 (-4.74 to 5.61)  +0.67 (-6.00 to 7.34) +0.10 (-6.57 to 6.76)  
HR 17.58 ± 3.60 16.89 ± 3.60 16.80 ± 3.60 17.11 ± 4.54 16.99 ± 4.53 16.88 ± 4.53 
Difference +0.79 (-3.34 to 4.91) +0.09 (-4.03 to 4.22)  +0.23 (-4.96 to 5.42) +0.11 (-5.08 to 5.29)  
FATzone AUC       
VO2 11.98 ± 1.95 11.30 ± 1.95 11.53 ± 1.95 11.35 ± 2.60 11.19 ± 2.60 11.35 ± 2.60 
Difference +0.45 (-1.79 to 2.69) -0.23 (-2.46 to 2.00)  -0.00 (-2.98 to 2.98) -0.16 (-3.14 to 2.81)  
HR 10.51 ± 1.44 9.85 ± 1.43 9.94 ± 1.43 9.84 ± 2.19 9.91 ± 2.18 10.26 ± 2.17 







FATzone low       
VO2 35.1 ± 4.2 35.3 ± 4.2 34.6 ± 4.2 34.7 ± 3.8 34.6 ± 3.8 34.2 ± 3.8 
Difference +0.5 (-4.3 to 5.4) +0.8 (-4.0 to 5.6)  +0.5 (-3.8 to 4.9) +0.5 (-3.9 to 4.8)  
HR 48.1 ± 5.0 46.5 ± 5.0 47.2 ± 5.0 48.3 ± 5.7 46.1 ± 5.7 47.6 ± 5.7 
Difference +0.9 (-4.9 to 6.7) -0.7 (-6.4 to 5.0)  +0.7 (-5.8 to 7.2) -1.5 (-8.0 to 5.0)  
FATzone high       
VO2 60.0 ± 4.3 59.1 ± 4.3 59.8 ± 4.3 60.2 ± 3.8 59.3 ± 3.8 59.6 ± 3.7 
Difference +0.2 (-4.7 to 5.0) -0.7 (-5.6 to 4.2)  +0.6 (-3.7 to 4.9) -0.2 (-4.6 to 4.1)  
HR 70.8 ± 4.4 68.6 ± 4.4 69.6 ± 4.4 71.5 ± 4.3 68.6 ± 4.3 70.9 ± 4.3 








Table 4.4 Mean ± SD. Participant characteristics used for group matching at baseline. 
Variable 4 mgday−1 12 mgday−1 Placebo 
Age (years) 25 ± 3 25 ± 5 26 ± 7 
Body mass (kg) 81.1 ± 10.1 79.2 ± 12.4 82.5 ± 6.1 
Body fat (%) 16.4 ± 4.9 16.4 ± 4.1 16.4 ± 2.5 
VO2peak (Lmin−1) 4.06 ± 0.43 4.03 ± 0.46 4.05 ± 0.47 
VO2peak (mLkg−1min−1) 50.6 ± 6.5 51.5 ± 6.6 49.1 ± 4.8 
FATmax (% VO2peak) 46.0 ± 9.3 49.2 ± 9.3 47.3 ± 8.4 
FATmax (% HRmax) 57.6 ± 11.0 61.0 ± 9.0 59.3 ± 10.3 
MFO VO2 (gmin−1)  0.49 ± 0.14 0.48 ± 0.13 0.49 ± 0.13 
MFO HR (gmin−1) 0.50 ± 0.14 0.48 ± 0.13 0.49 ± 0.12 
MFOFFM VO2 (mgkg−1min−1) 7.28 ± 1.87 7.24 ± 1.54 7.07 ± 1.59 








Table 4.5 Mean ± SD. Groups characteristics used to infer potential changes in training status from pre- to post-supplementation. 
Variable 4 mgday−1 12 mgday−1 Placebo 
Baseline Week 8 Baseline Week 8 Baseline Week 8 
VO2peak (Lmin−1) 4.06 ± 0.43 4.08 ± 0.38 4.03 ± 0.46 4.04 ± 0.53 4.05 ± 0.47 4.01 ± 0.40 
VO2peak (mLkg−1min−1) 50.6 ± 6.5 50.8 ± 6.5 51.5 ± 6.6 51.6 ± 6.5 49.1 ± 4.8 48.7 ± 4.3 
Body mass (kg) 81.1 ± 10.1 81.0 + 9.2 79.2 ± 12.4 79.0 ± 11.5 82.5 ± 6.1 82.4 ± 6.0 





Table 4.6 Overview of CV calculations for each primary outcome variable measured 
during the current study. 
Variable Mean SD CV 
FATmax (% VO2peak) 48.3 3.6 7.5% 
FATmax (% HRmax) 60.1 3.3 5.5% 
FATmin (% VO2peak) 86.7 4.5 5.2% 
FATmin (% HRmax) 92.0 3.0 3.2% 
MFO VO2 (gmin−1)  0.48 0.06 13.2% 
MFO HR (gmin−1) 0.48 0.06 13.4% 
MFOFFM VO2 (mgkg−1min−1) 7.04 0.93 13.2% 
MFOFFM HR (mgkg−1min−1) 7.02 0.94 13.4% 
VO2 AUC submax (g) 22.17 4.04 18.2% 
HR AUC submax (g) 17.60 2.98 16.9% 
VO2 AUC FATzone (g) 11.77 1.78 15.1% 
HR AUC FATzone (g) 10.55 1.58 15.0% 
FATzone low (% VO2peak) 35.4 3.5 9.9% 
FATzone low (% HRmax) 48.4 3.8 7.8% 
FATzone high (% VO2peak) 60.6 3.6 5.9% 







The current study aimed to investigate whether supplementation with 4 mgday−1 or 
12 mgday−1 astaxanthin for 4 or 8 weeks could induce changes in the fat oxidative 
capacity as measured during the completion of a FATmax protocol in recreationally 
active males. The study outcomes suggest that astaxanthin did not exert an effect on 
the fat oxidative capacity, with indices relating to MFO and FATmax remaining 
unchanged following astaxanthin supplementation when compared to the placebo. 
The use of a FATmax protocol in the current study enabled the measurement of whole-
body fat oxidation rates over a wide range of exercise intensities. Therefore, when 
compared to previous research (Earnest et al., 2011, Res et al., 2013), the ability to 
detect astaxanthin-induced changes in the fat oxidative capacity would not have been 
confounded by the high inter-individual variability often reported for measures of fat 
oxidation during exercise (Venables, Achten and Jeukendrup, 2005). Despite this key 
methodological difference, the outcome of the current study is similar to those 
reported during the completion of a single-intensity, steady-state preload (Earnest et 
al., 2011, Res et al., 2013). Indeed, 4 weeks of 4 mgday−1 astaxanthin supplementation 
has been previously reported to not influence measures of RER or whole-body fat and 
carbohydrate oxidation rates obtained during a 2 h submaximal cycle at 5% below the 
lactate threshold (Earnest et al., 2011). Likewise, 20 mgday−1 astaxanthin for 4 weeks 
did not influence measures of RER or whole-body fat or carbohydrate oxidation rates 
obtained during the completion of a 1 h steady-state cycle at 50% Wmax (Res et al., 




mgday−1 and 12 mgday−1, with no differences in MFO, FATmax or FATzone reported 
during a FATmax protocol following both 4 weeks and 8 weeks of supplementation. 
The metabolic findings of this study are, therefore, in contrast with those typically 
reported in mice exercise models following 3-5 weeks of astaxanthin intake (Ikeuchi 
et al., 2006, Aoi et al., 2008). Supplementation with 30 mgkg−1 astaxanthin for 3 
weeks, for example, was reported to significantly increase concentrations of plasma 
NEFA during a 15 min swim against an additional 5% body mass (Ikeuchi et al., 
2006). In the same study, an increase in fat utilisation was also inferred, with muscle 
glycogen concentrations significantly greater post-exercise in mice supplementing 
with either 6 mgkg−1 or 30 mgkg−1 astaxanthin for 5 weeks (6 mgkg−1 group: 4.0 
mgg−1 vs. 30 mgkg−1 group: 4.2 mgg−1 vs. control group: 3.4 mgg−1). Whole-body 
fat oxidation rates (mgkg−1min−1) have also been reported as 21% greater during the 
completion of a 60 min run (25 mmin−1) in mice supplementing with 0.02% ww−1 
astaxanthin for 4 weeks when compared to an exercising control (Aoi et al., 2008). 
A simple explanation for the disparity in study outcomes between human and mice 
research could be the difference in astaxanthin dose administered to each species. In 
mice exercise models, for example, astaxanthin doses of 6 mgkg−1 and 30 mgkg−1 
have been administered over a 3-5 week supplementation period (Ikeuchi et al., 2006). 
If the same dose were to be administered in the current study, participants would have 
supplemented with either 486 mgday−1 or 2430 mgday−1 astaxanthin, doses that are 
far greater than the 4 mgday−1 or 12 mgday−1 that were safely administered. With 




supplementation and the fat oxidative capacity, this may partially explain why a 
metabolic effect of astaxanthin has yet to be replicated in exercising humans. 
A limitation of the FATmax protocol used in the current study is the variation reported, 
with primary outcome measures of MFO, FATmax, FATzone, AUC and FATmin having 
CVs in the range of 3.2-18.2% (4.3.6 Coefficient of Variation Calculations). 
Therefore, despite enabling the description of whole-body fat oxidation over a wide 
range of exercise intensities, the detection of small changes in fat oxidation may have 
been difficult due to the variation present. The use of a prolonged 8 week 
supplementation strategy also required the use of a parallel groups design, with 
participants matched based upon specific characteristics as described in 4.2.4. Group 
Matching. As such, participants were not able to act as their own control, with subtle 
differences in participant characteristics and individual responses to astaxanthin 
supplementation potentially confounding the ability to detect small changes in each 
outcome variable. 
In conclusion, supplementation with 4 mgday−1 or 12 mgday−1 astaxanthin for 4 
weeks and 8 weeks did not improve measures of exercising fat oxidative capacity in 
recreationally active males. This may have been implicated by the variation present in 
the experimental design/protocol or the differences in the astaxanthin doses 
administered between mice and human experimental models. Future research should 
aim to reduce the variation present in its outcome measures while also implementing 
a supplementation strategy that would allow participants to act as their own control, 









5. Astaxanthin Supplementation Improves Performance and Fat 





Dietary supplementation strategies that can modify substrate utilisation patterns have 
received widespread attention in the literature, especially with regard to enhancing fat 
metabolism during exercise (Hawley, Brouns and Jeukendrup, 1998, Yeo et al., 2011, 
Burke, 2015). One such supplement is astaxanthin, a liposoluble carotenoid usually 
supplemented through the intake of H. pluvialis-derived antioxidant products. Based 
upon research conducted in mice, improvements in endurance performance are 
typically reported following 3-5 weeks of astaxanthin intake (Ikeuchi et al., 2006, Aoi 
et al., 2008, 2018). This is attributed to the potential for this liposoluble antioxidant to 
indirectly enhance the fat oxidative capacity during exercise through protecting the 
mitochondria from oxidative modifications induced by RONS (Aoi et al., 2008). 
In humans, a similar ergogenic benefit was reported in trained cyclists, with 4 weeks 
of 4 mgday−1 astaxanthin significantly improving 20 km cycling TT performance 
when compared to a placebo (mean improvement (MI) = astaxanthin: 121 s (5.1%) vs. 
placebo: 18 s (0.8%)) (Earnest et al., 2011). Conversely, in a 1 h cycling TT an 
ergogenic benefit was not reported following a 4 week supplementation with either 20 
mgday−1 astaxanthin (MI = 74 s (2.1%)) or an appearance-matched placebo (MI = 52 
s (1.4%)) in trained cyclists or triathletes (Res et al., 2013). Although there is no clear 
explanation for the disparity between the two findings, it should be noted that 
astaxanthin did not influence measures of substrate utilisation obtained in either study 
(Earnest et al., 2011, Res et al., 2013). This outcome was also replicated in Chapter 4, 
whereby supplementation with 4 mgday−1 or 12 mgday−1 astaxanthin for both 4 




during the completion of a FATmax protocol in recreationally active, male participants. 
As the enhancement of the fat oxidative capacity is the mechanism by which 
astaxanthin is purported to exert its ergogenic potential, the absence of this effect may 
implicate an alternative ergogenic mechanism in Earnest et al. (2011), or partially 
explain the absence of a performance effect in Res et al. (2013). 
A 3-5 week supplementation strategy is seemingly advocated in mice-models when 
seeking to elicit the ergogenic potential of astaxanthin during endurance exercise 
(Ikeuchi et al., 2006, Aoi et al., 2008, 2018). In human performance studies, although 
equivocal findings are reported, one key methodological consistency to mice research 
is the 3-5 week supplementation strategy implemented by both Earnest et al. (2011) 
and Res et al. (2013), respectively. Interestingly, plasma astaxanthin concentrations 
are reported to peak within the first week of intake, even when consumption is chronic. 
Rüfer et al. (2008), for example, quantified the uptake of ~ 1.25 mgday−1 astaxanthin 
in the plasma of 28 healthy males over a 4 week period and reported a peak in 
concentration following 6 days of intake (Rüfer et al., 2008). This finding enables 
shorter supplementation periods to be advocated, which in turn may allow the use of 
a randomised crossover study design. 
As such, the current study implements a shorter 7 day supplementation period, 
interspersed by 14 days of washout, to ensure that participants could act as their own 
control. A 40 km cycling TT was also used as a reliable measure of endurance 
performance obtained during a race distance that is common in competitive cycling 
events (Palmer et al., 1996, Laursen, Shing and Jenkins, 2003, Currell and Jeukendrup, 




compared to studies conducted previously (Earnest et al., 2011, Res et al., 2013). 
Therefore, the aim of the current study was to investigate whether supplementation 
with 12 mgday−1 astaxanthin for a shorter 7 day period can improve exercise 
performance and metabolism during the completion of a 40 km cycling TT in 
recreationally trained male cyclists using a randomised, crossover design. 
 
5.2. Methods 
5.2.1.  Participants 
Twelve recreationally trained male cyclists (age: 28 ± 6 years, height: 1.78 ± 0.07 m, 
body mass: 78.3 ± 7.6 kg, body fat: 13.7 ± 2.6%, VO2peak: 56.5 ± 5.5 mLkg
−1min−1, 
Wmax: 347 ± 38 W) provided written informed consent and participated in the study. 
Participants were not permitted to supplement with additional antioxidants/vitamins 
alongside those provided in the current study. A list of commonly consumed 
astaxanthin-rich foods to avoid was also provided to limit the additional dietary intake 
of astaxanthin during supplementation. Participants were also instructed to refrain 
from strenuous exercise and the consumption of alcohol and caffeine in the 24 h 
preceding each visit (Rosenberg et al., 1978, Westerterp-Plantenga et al., 2006), and 
to enter the laboratory in a 4 h postprandial state, except for the ingestion of water to 
ensure euhydration. Compliance with the above procedures was checked via 24 h 
dietary recall, with participants asked to replicate dietary intake prior to each trial. All 
participants visited the laboratory on four separate occasions (two preliminary trials 
and two experimental trials) at a similar time of day (± 1 h). A randomised, double-




5.2.2.  Preliminary Trials 
During the first preliminary visit participants completed a GXT to volitional 
exhaustion using an electromagnetically braked cycle ergometer. Following 5 min of 
unloaded pedalling, the GXT commenced at 75 W and work rate was increased by 30 
W every 1 min until volitional exhaustion. Participants selected a preferred cadence 
to maintain throughout, with volitional exhaustion defined as an inability to maintain 
> 60% of this cadence for > 5 s despite strong verbal encouragement. Breath-by-breath 
expired air was collected for VO2peak determination and was defined as the highest 30 
s average of VO2 recorded during the GXT. Heart rate and RPE (Borg, 1982) for the 
whole-body (RPEO) and the lower limbs (RPEL) were also collected throughout the 
test. A familiarisation with the 40 km TT and the experimental procedures employed 
was then undertaken during a second preliminary visit to ensure participants were 
accustomed to procedures employed during each experimental trial. 
The importance of an initial familiarisation has been demonstrated in trained, male 
cyclists following the completion of a 40 km TT on three separate occasions (Laursen, 
Shing and Jenkins, 2003). Indeed, when performance data was compared across all 
three TTs a CV of 3.0 ± 2.9% was reported, however, when performance data was 
compared between the second and third TT only, a markedly lower CV of 0.9 ± 0.7% 
was reported. As such, the use of a familiarisation TT was strongly recommended to 
ensure the accurate and reliable assessment of 40 km TT performances, even when 
trained cyclists are recruited (Laursen, Shing and Jenkins, 2003). 
Following the familiarisation trial participants received one of two randomised 




period was then undertaken based upon estimations made using the pharmacokinetic 
data reported in Mercke Odeberg et al. (2003) and the calculations detailed in Saha 
(2018). Following this 14 day washout period, participants then supplemented with 
the second supplement for the 7 days preceding the second experimental trial. Further 
information detailing how these estimations were made are provided in section 2.4. 
(Treatment) above. Supplementation consisted of either 12 mgday−1 astaxanthin 
(AstaReal®, Sweden) or an appearance-matched placebo with no viable constituents 
(AstaReal®, Sweden). Participants ingested two capsules daily (one morning and one 
evening), with compliance ensured via daily text message reminders and a pill count 
post-ingestion. To ensure the study remained double-blind, each supplement was 
provided with a randomised alphanumerical code until after data analysis was 
complete. 
 
5.2.3.  Experimental Trials 
On the day of each experimental trial, participants entered the laboratory and 
undertook a 5 min warm-up before completing a best effort 40 km cycling TT on a 
Velotron Racermate cycle ergometer (Velotron, USA). Preferred frame geometry 
(i.e. handlebar and saddle position) was selected by the participant and was replicated 
for each experimental trial. Information regarding cadence, gear and distance covered 
was received, with no other information or external encouragement provided. Time to 
complete and mean power were recorded for both the total distance and for each 10 
km quartile during the TT. Heart rate, RPEO, RPEL and ratings of fatigue (ROF) 




sample was also taken at rest and every 10 km during the TT and was immediately 
analysed for indices of blood lactate (Lactate Pro 2, Japan) (CV = 2.7-5.1% 
(Bonaventura et al., 2015)), glucose (Hemocue, Sweden) (CV = 1.8%  (Rajadhyaksha, 
Rodriguez and Nichols, 2007)) and triglycerides (Reflotron, USA) (CV = 0.8-9.9% 
(Statland, 1990)). Breath-by-breath expired air was obtained during the 10th, 20th, 30th 
and 40th km of the TT. Respiratory gas data were then used to calculate whole-body 
fat and carbohydrate oxidation rates (FATox and CHox, respectively) using the 
method of Jeukendrup and Wallis (2005). 
 
5.2.4.  Statistical Analysis 
Data was first analysed for normality and homogeneity using the Shapiro-Wilk test 
and the Levene’s test, respectively. A paired t-test was then used to compare group 
differences [astaxanthin vs. placebo] in performance time and mean power, and to 
determine whether a trial order effect [Trial 1 vs. Trial 2] was present for both 
performance time and mean power. A two-way condition [astaxanthin vs. placebo] x 
time [10, 20, 30, 40 km] ANOVA was used to determine differences in performance 
variables (time and power), respiratory variables (FATox and CHox, RER, VO2), 
perceptual variables (RPEO, RPEL, ROF) and HR. Blood metabolites (lactate, glucose, 
triglycerides) were also analysed using a two-way condition [astaxanthin vs. placebo] 
x time [rest, 10, 20, 30, 40km] ANOVA. If a significant main effect or interaction was 
observed, post-hoc analysis was performed with a Bonferroni adjustment. Effect sizes 
were calculated using Hedge’s g for paired comparisons and were interpreted as trivial 




Hedge’s g correction was used to mitigate the positive bias of the Cohen’s d effect 
size when n < 20 (Lakens, 2013). Confidence intervals (± 95%) were also calculated 
and are reported where necessary. Descriptive data are displayed as mean ± SD. 
Statistical analysis was conducted using a statistical software package (SPSS, Version 
25, USA), with significance accepted at p < 0.05. 
 
5.3. Results 
5.3.1.  Performance Variables 
Time to complete the 40 km TT (Figure 5.1a) was significantly improved from 70.76 
 3.93 min in the placebo condition to 69.90  3.78 min in the astaxanthin condition, 
which equates to a 1.2  1.7% improvement in performance (MI = 51  71 s, 95% CI 
= 6-96 s, p = 0.029, g = 0.21). Mean power (Figure 5.1c) was also significantly 
improved from 213.8  29.0 W in the placebo condition to 219.9  28.7 W in the 
astaxanthin condition, which equates to an improvement of 2.8  4.1% (MI = 6.1  
9.5 W, 95% CI = 0.1-12.1 W, p = 0.047, g = 0.20). Participants were also significantly 
faster (-21  28 s, 95% CI = -3 to -39 s, p = 0.026, g = 0.34; Figure 5.1b) and produced 
significantly greater power (+9.5  13.9 W, 95% CI = 0.6-18.3 W, p = 0.038, g = 0.32; 
Figure 5.1d) between 20-30 km in the astaxanthin condition. No performance 
differences were reported during any other 10 km quartile (p > 0.083). No trial order 
was present for performance time (Trial 1: 70.41  4.01 min vs. Trial 2: 70.25  3.75 
min, p = 0.993, g = 0.04) or mean power (Trial 1: 216.6  29.4 W vs. Trial 2: 217.2  




5.3.2.  Respiratory Variables 
A [group x time] interaction was observed for FATox (p = 0.037), whereby FATox 
was significantly greater between 39-40 km following astaxanthin supplementation 
(Figure 5.2c), increasing from 0.13  0.04 gmin−1 in the placebo condition to 0.22  
0.05 gmin−1 in the astaxanthin condition (+0.09  0.13 gmin−1, 95% CI = 0.00-0.17 
gmin−1, p = 0.044, g = 0.52). A similar [group x time] interaction was also observed 
for RER (p = 0.007), whereby RER was also significantly lower between 39-40 km 
following astaxanthin supplementation (Figure 5.2a), decreasing from 0.99  0.02 in 
the placebo condition to 0.96  0.01 in the astaxanthin condition (-0.03  0.04, 95% 
CI = -0.01 to -0.06, p = 0.024, g = 0.60). For measures of CHox a [group x time] 
interaction was also present (p = 0.037), with CHox significantly greater at 39-40 km 
in both conditions (p < 0.045). There was, however, no differences reported between 
conditions for CHox at any time point during the TT (p > 0.118; Figure 5.2e). 
 
5.3.3.  Blood Metabolites 
Lactate (Figure 5.2b) was significantly increased above baseline throughout the TT (p 
< 0.001) and was also significantly greater at 40 km compared to 30 km (p = 0.002). 
Glucose (Figure 5.2f), in contrast, was significantly lower throughout the TT when 
compared to baseline (p < 0.003), and triglycerides (Figure 5.2d) were significantly 
increased above baseline at 30 km (p = 0.027) and 40 km (p = 0.002), as well as being 
significantly greater at 40 km than at any other time point (p < 0.003). There were no 




5.3.4. Perceptual Variables and Heart Rate 
Ratings of fatigue (p < 0.001), RPEO (p < 0.001) and RPEL (p < 0.001) all increased 
progressively over time with no effect of condition (p > 0.131). A main effect of time 
was also present for HR (p < 0.001) and VO2 (p < 0.001) in both conditions (p > 0.338), 
with HR significantly greater at 40 km than at each previous time point and VO2 
significantly greater at 30 km than at 20 km and at 40 km when compared to each 






Figure 5.1 Mean ± SD. Individual values for performance time (a) and power output 
(c) during the 40 km time trial following each condition. Data for 10 km quartile 
performance times (b) and power outputs (d) are also displayed as mean (± SD) for 
each condition. * denotes a significant difference between conditions, # denotes a 
significant difference to the first time point, δ denotes a significant difference to the 





Figure 5.2 Mean ± SD. Respiratory measures of the respiratory exchange ratio (RER) 
(a), whole-body fat oxidation rates (FATox) (c), whole-body carbohydrate oxidation 
rates (CHox) (e), and blood metabolites lactate (b), triglycerides (d) and glucose (f) 
obtained over the duration of each 40 km time trial. * denotes a significant difference 
between conditions, # denotes a significant difference to baseline, δ denotes a 
significant difference to the previous time point, † denotes significant difference to all 








Table 5.1 Mean ± SD. Physiological and perceptual results. δ denotes a significant difference to the previous time point, † denotes a 
significant difference to all previous time points (p < 0.05). 
Variable Astaxanthin Placebo 
 10 km 20 km 30 km 40 km 10 km 20 km 30 km 40 km 
VO2 (mLkg−1min−1) 41.0 ± 7.6 40.1 ± 7.6 40.6 ± 8.2 
δ 46.3 ± 8.6 † 39.6 ± 5.8 39.2 ± 6.9 41.1 ± 6.6 δ 45.2 ± 7.4 † 
HR (beatsmin−1) 153 ± 10 155 ± 9 156 ± 10 171 ± 10
 † 153 ± 13 154 ± 11 156 ± 11 171 ± 9 † 
ROF 3.7 ± 1.5 5.2 ± 1.3 δ 6.6 ± 1.3 δ 8.1 ± 1.6 † 3.2 ± 1.2 5.0 ± 1.5 δ 5.8 ± 1.7 δ 7.6 ± 1.8 † 
RPEO 13.8 ± 1.4 14.9 ± 1.4 
δ 16.3 ± 1.4 δ 18.1 ± 1.3 † 13.3 ± 1.7 14.8 ± 1.5 δ 16.2 ± 1.5 δ 18.3 ± 1.8 † 
RPEL 14.9 ± 1.7 16.0 ± 1.2 







The current investigation is the first to demonstrate an increase in whole-body fat 
oxidation (FATox) and a corresponding reduction in RER during endurance exercise 
in humans supplementing with astaxanthin. This study also reports a small, yet 
significant, ergogenic benefit from 12 mgday−1 astaxanthin supplementation for 7 
days in recreationally trained male cyclists completing a 40 km cycling TT. This 
equates to a mean 51 s (1.2%) time improvement when compared to placebo. 
The shorter 7 day supplementation strategy implemented in the current study enabled 
the use of a randomised crossover design and may provide a methodological insight 
as to why a metabolic effect of astaxanthin has been observed. In previous research, 
including Chapter 4, the application of a prolonged supplementation strategy has 
required the use of parallel group designs, with participants often matched based upon 
specific baseline demographics (i.e. fitness characteristics and anthropometry) 
(Earnest et al., 2011, Res et al., 2013). A potential advantage of the current study is, 
therefore, the ability to implement a randomised crossover design as this enabled each 
participant to act as their own control, minimising the potential impact subtle 
differences in participant characteristics and individual responses to astaxanthin could 
have upon the outcome variable (Cleophas and de Vogel, 1998, Burke and Peeling, 
2018). As such, this would have improved the statistical power of the study and may 
have increased the ability to detect subtle differences in substrate utilisation during 
exercise, with FATox known to vary considerably between individuals of similar 
fitness demographics, even at the same absolute and relative exercise intensities 




The performance and metabolic findings of this study are consistent with those 
typically reported in mice following 3-5 weeks of astaxanthin intake (Ikeuchi et al., 
2006, Aoi et al., 2008). Indeed, continuous improvements in swim TTE were reported 
from 1 week onwards in mice fed 6 or 30 mgkg−1 astaxanthin for 5 weeks (Ikeuchi et 
al., 2006). Similarly, 0.02 ww−1 astaxanthin for 4 weeks enhanced TTE at a running 
intensity of 30 mmin−1 in comparison to an exercising control (astaxanthin: 67.53 ± 
4.20 min vs. control: 50.40 ± 5.00 min) (Aoi et al., 2008). In the same study, RER was 
also significantly lower from 20 min onward during a 60 min run (25 mmin−1), with 
FATox also higher in the astaxanthin group (Aoi et al., 2008). This highlights 
similarities with the present study following a smaller relative dose of astaxanthin (~ 
0.15 mgkg−1), with changes in FATox (+0.09 gmin−1) and RER (-0.03) only reported 
in the latter stages (39-40 km) of the 40 km cycling TT. Furthermore, with these 
changes occurring at the same relative exercise intensity, with no difference in VO2 
reported between groups at this time point (astaxanthin: 46.3 ± 8.6 mLkg−1min−1 vs. 
placebo: 45.2 ± 7.4 mLkg−1min−1), this provides further evidence to an increased 
utilisation of fat during this endurance performance event. 
Possible explanations for these observations are received from previous exploratory 
research. Astaxanthin, for example, is known to accumulate in the mitochondrial 
membrane following consumption where it is suggested to indirectly enhance FATox 
during exercise through protecting CPT1 from RONS-induced oxidative 
modifications (Aoi et al., 2008, Wolf et al., 2010, Kidd, 2011). Alternatively, the 
expression of AMPK, is also reported to be upregulated following astaxanthin intake 




implicated in the stimulation of fatty acid oxidation; the transportation of fatty acids 
into the mitochondria, potentially through the intercalation of CPT1 and FAT/CD36; 
as well as the upregulation of many transcription factors, such as PGC-1α, that are 
known to promote mitochondrial biogenesis and control mitochondrial oxidative 
capacity (Thomson and Winder, 2009). As this mechanistic insight is received 
exclusively from in vitro and in vivo mice-models, it is clear that future exploratory 
research is necessary to elucidate similar mechanistic information in exercising 
humans, implementing performance tests of a similar or longer duration (> 1 h) so that 
the ergogenic potential of astaxanthin can be explored in more detail.  
The performance findings of this study are also consistent with those reported by 
Earnest et al. (2011), as 4 weeks of 4 mgday−1 astaxanthin improved 20 km cycling 
TT performance in trained male cyclists (Earnest et al., 2011). Furthermore, the 121 s 
time improvement (5.1%) reported in the astaxanthin group was also significantly 
greater than the corresponding 18 s improvement (0.8%) reported in the placebo, 
suggesting a treatment effect was present (Earnest et al., 2011). In contrast, an 
ergogenic benefit was not reported during a 1 h cycling TT in trained male cyclists or 
triathletes following 4 weeks of supplementation with either 20 mgday−1 astaxanthin 
(MI = 74 s (2.1%)) or an appearance-matched placebo (MI = 52 s (1.4%)) (Res et al., 
2013). Although there is no clear explanation for the disparity between the two studies 
(Earnest et al., 2011, Res et al., 2013), it should be noted that neither Earnest et al. 
(2011) nor Res et al. (2013) reported differences in substrate utilisation during 
exercise, implicating an alternative ergogenic mechanism in Earnest et al. (2011), or 




Four weeks of 4 mgday−1 astaxanthin supplementation, for example, did not influence 
measures of RER, CHox or FATox obtained during a 2 h submaximal cycle at 5% 
below the lactate threshold (Earnest et al., 2011). Likewise, 20 mgday−1 astaxanthin 
for 4 weeks did not influence measures of RER, CHox or FATox obtained during the 
completion of a 1 h steady-state cycle at 50% Wmax (Res et al., 2013). As such, the 
increase in FATox and the decrease in RER reported in the latter stages of exercise in 
the current study are in contrast with previous research (Earnest et al., 2011, Res et 
al., 2013). A possible explanation for this is that the current study measured substrate 
utilisation during the completion of an ecologically valid performance event and not 
during a single-intensity, steady-state preload (Earnest et al., 2011, Res et al., 2013). 
As such, when compared to previous research (Earnest et al., 2011, Res et al., 2013), 
the metabolic measures obtained during the 40 km TT may have more accurately 
reflected the ergogenic mechanism by which astaxanthin is purported to improve 
performance during best effort endurance events. 
Finally, as astaxanthin uptake was not quantified in the current investigation, the 7 day 
supplementation strategy was informed by previous literature that reported astaxanthin 
concentrations peak within the first week of intake, even when consumption is chronic 
(Rüfer et al., 2008). Nevertheless, an ergogenic and metabolic effect of astaxanthin 
was demonstrated following this shorter 7 day strategy, thus an exploration of the 
human pharmacokinetics of astaxanthin is clearly required so that an optimal 
supplementation strategy can be designed and implemented for future practice within 




To conclude, supplementation with 12 mgday−1 astaxanthin for 7 days provided an 
ergogenic benefit to 40 km cycling TT performance in recreationally trained male 
cyclists and enhanced whole-body fat oxidation in the final stages of this endurance-
type performance event. Future research should seek to determine an optimal 
supplementation strategy for astaxanthin intake based on pharmacokinetics, while 
exploring the underlying mechanistic factors by which astaxanthin is purported to 















The aim of this thesis was to investigate the effects of astaxanthin supplementation on 
indices of exercise recovery, metabolism and performance in exercising humans. A 
summary of the outcomes reported in each experimental chapter are provided below: 
Study 1 (Chapter 3): The aim of this study was to investigate whether prolonged 
supplementation with 4 mgday−1 or 12 mgday−1 astaxanthin for 8 weeks could 
attenuate various markers of muscle damage and improve the recovery of muscle 
function in the 48 h following a 30 min bout of eccentric exercise. This study 
recruited recreationally active males unaccustomed to eccentric exercise and 
high-force resistance training to ensure that the repeated-bout effect synonymous 
with eccentric exercise did not confound the study results. Despite this, the 
outcomes reported suggest that astaxanthin does not provide a recovery benefit 
following the completion of muscle damaging exercise, with no effect of 
supplement reported for any of the primary outcome measures obtained in this 
study. 
Study 2 (Chapter 4): The aim of this study was to investigate whether 4 weeks 
or 8 weeks of astaxanthin supplementation (4 mgday−1 and 12 mgday−1) could 
enhance the fat oxidative capacity, namely the MFO and FATmax, in recreationally 
active males completing a FATmax protocol. The use of a FATmax protocol enabled 
this study to be the first to determine the effects of astaxanthin on whole-body fat 
oxidation during exercise of varying submaximal intensities. Similar outcomes 




measures of the fat oxidative capacity obtained during exercise after 4 weeks and 
8 weeks of supplementation. 
Study 3 (Chapter 5): The aim of this study was to investigate whether a shorter 
7 day supplementation with 12 mgday−1 astaxanthin could improve exercise 
performance and metabolism during a 40 km cycling TT in recreationally trained 
male cyclists. This study was the first conduct a randomised crossover design 
when investigating the ergogenic and metabolic effect of astaxanthin in exercising 
humans. This study was also the first to demonstrate an increase in whole-body 
fat oxidation and a simultaneous reduction in RER during endurance exercise in 
humans supplementing with astaxanthin. Furthermore, a small, yet significant, 
ergogenic benefit of 7 days astaxanthin supplementation was also reported, with 
a mean 51 s (1.2%) time improvement reported when compared to the placebo. 
Together, the outcomes reported in this thesis demonstrate an ergogenic and a 
corresponding metabolic effect of astaxanthin supplementation; but also report a null 
effect of astaxanthin supplementation on indices of exercise-induced muscle damage 
and submaximal fat oxidation in recreationally active/trained male individuals. 
A potential mechanistic explanation for these findings is received from previous 
exploratory research that has focussed on the function of astaxanthin in the 
mitochondrial membrane (Aoi et al., 2008, Wolf et al., 2010, Kidd, 2011). 
Astaxanthin, for example, is known to accumulate in the mitochondrial membrane 
following consumption, where it is reported to indirectly enhance whole-body fat 
oxidation during exercise through protecting CPT1 from RONS-induced oxidative 




reported to upregulate the expression of AMPK (Aoi et al., 2018), a key enzyme 
implicated in the stimulation of fatty acid oxidation; the transportation of fatty acids 
into the mitochondria, potentially through the intercalation of CPT1 and FAT/CD36; 
as well as the upregulation of many transcription factors, such as PGC-1α, that are 
known to promote mitochondrial biogenesis and control mitochondrial oxidative 
capacity (Thomson and Winder, 2009). 
As the mitochondria is an important predictor of endurance performance (Bishop et 
al., 2019), with its content and function significantly correlated with VO2max (van der 
Zwaard et al., 2016) and TT performance (Granata et al., 2016), it is perhaps to be 
expected that a beneficial effect of astaxanthin supplementation would be reported in 
the experimental protocol (Chapter 5) that most accurately reflected this proposed 
mitochondrial mechanism. Future research should, therefore, be conducted to explore 
this ergogenic mechanism in more detail, implementing a performance TT of a similar 
or longer duration (> 1 h) to the 40 km cycling TT implemented in Chapter 5. 
The following sections are written to further discuss the general findings of this thesis, 
with limitations, practical implications and future directions for astaxanthin research 
also provided. 
 
6.2. Differences Between Mice and Human Astaxanthin Research 
It should first be noted that outcomes reported in an animal model are not always 
replicable in a human model (Shanks, Greek and Greek, 2009). Therefore, disparities 
in the outcomes reported between mice and human astaxanthin research may simply 




Mice, for example, have a specific metabolic rate (metabolic rate per g of body mass) 
that is ~ 7 times greater than that of the average human (Demetrius, 2005). This 
relative increase in energy production is likely related to size-dependent differences 
in thermoregulation and heat loss, but also the increased requirement for nutrient 
supply (capillary density) and demand (mitochondrial density) in the muscle tissue of 
mice (Perlman, 2016). A consequence of this relative increase in metabolically active 
tissue and mitochondrial activity is the greater rate of RONS production and oxidative 
damage that typically occurs in mice when compared to humans (Demetrius, 2005, 
Perlman, 2016). With astaxanthin known to accumulate in the mitochondrial 
membrane following consumption and provide a protection against RONS-induced 
detriments to its function (Wolf et al., 2010, Kidd, 2011), the greater specific 
metabolic rate of mice may provide a genetic predisposition that partially explains 
why mice-models typically seem more responsive to astaxanthin supplementation than 
do humans. 
An alternative explanation may be the difference in the astaxanthin dose administered 
in each of these experimental models. In mice, for example, astaxanthin doses of 6 
mgkg−1 and 30 mgkg−1 have been administered over a 3-5 week supplementation 
period (Ikeuchi et al., 2006). If the same dose would have been administered in this 
thesis, participants (~ 80.4 kg body mass) would have been provided with either 482 
mgday−1 or 2412 mgday−1 astaxanthin which are doses far greater than the 4 mgday−1 
(~ 0.05 mgkg−1) or 12 mgday−1 (~ 0.15 mgkg−1) safely administered. With a dose-
response relationship reported in mice for the beneficial effects of astaxanthin intake 




are reported consistently in mice following higher relative doses, whereas similar 
effects remain equivocal in human research. 
The ability for human research to increase the dose of astaxanthin administered is, 
however, potentially constrained by the safety recommendations currently advocated 
by EFSA (EFSA FEEDAP Panel, 2014, EFSA NDA Panel, 2014). Indeed, an ADI of 
0.034 mgkg−1day−1 astaxanthin is currently advocated based upon research 
conducted in rats (EFSA FEEDAP Panel, 2014), which would equate to a dose of ~ 
2.97 mgday−1 in the current thesis. It was also concluded that the safety of 0.06 
mgkg−1day−1 astaxanthin (~ 4.82 mgday−1 in the current thesis) had yet to be fully 
established for human consumption (EFSA NDA Panel, 2014). 
There were, however, no adverse effects reported by the participants recruited to this 
thesis in response to supplementation with 4 mgday−1 or 12 mgday−1 astaxanthin for 
7 days, 4 weeks or 8 weeks, respectively. Furthermore, no adverse effects were 
reported previously following the acute intake of 40 mg astaxanthin (Mercke Odeberg 
et al., 2003), or the chronic supplementation of 6-40 mgday−1 astaxanthin for 4-8 
weeks (Spiller and Dewell, 2003, Kupcinskas et al., 2008, Res et al., 2013). The 
possible adverse effects measured in each of these studies ranged from headaches and 
perceptions of abdominal/stomach pain, to blood pressure and biochemical 
parameters, including a metabolic panel and cell blood count (Mercke Odeberg et al., 
2003, Spiller and Dewell, 2003, Kupcinskas et al., 2008). Together, each of these 
studies suggest that it may be possible to safely advocate both acute and chronic 
intakes of astaxanthin that are considerably greater than the current ADI. Future 




consumption guidelines can be adjusted accordingly, potentially enabling the use of 
an increased dose when seeking to elucidate the beneficial properties of astaxanthin in 
an exercising human cohort. 
In mice experimental models, indices of substrate utilisation, oxidative stress and 
inflammation have also been measured in the skeletal and cardiac muscle in addition 
to the plasma and/or serum (Aoi et al., 2003, 2008, Lee et al., 2003, Ikeuchi et al., 
2006, Liu et al., 2014). In comparison, human research (including the current thesis) 
has relied upon biomarkers obtained from the plasma/serum to provide a global 
snapshot of the effect of astaxanthin in exercising humans (Bloomer et al., 2005, 
Earnest et al., 2011, Djordjevic et al., 2012, Res et al., 2013, Baralic et al., 2015). This 
is a potential limiting factor to human research conducted thus far, with the extraction 
of muscle tissue in mice providing a more sophisticated means of detecting 
astaxanthin-induced changes in markers of substrate utilisation, oxidative stress and/or 
inflammation. Future research should, therefore, seek to obtain muscle biopsy data 
from exercising humans so that the effects of astaxanthin supplementation can be 
explored in more detail at an intramuscular level. 
 
6.3. Experimental Study Designs 
The current thesis has employed two experimental study designs to investigate the 
efficacy of astaxanthin supplementation in exercising humans. In Chapter 3 and 
Chapter 4 a parallel groups design was employed due to the use of a prolonged 8 week 
supplementation strategy, with participants matched based upon specific baseline 




Chapter 5, the shorter 7 day supplementation strategy implemented enabled the use of 
a randomised crossover design, with participants acting as their own control. 
Interestingly, a beneficial effect of astaxanthin was only reported in Chapter 5 of this 
thesis, with 7 days of 12 mgday−1 astaxanthin supplementation significantly 
improving 40 km cycling TT performance and whole-body fat oxidation in 
recreationally trained male cyclists. This is contrast to Chapter 3 and Chapter 4, 
whereby supplementation with 4 mgday−1 or 12 mgday−1 astaxanthin for 4-8 weeks 
did not attenuate the muscle damage response to exercise or enhance the fat oxidative 
capacity during submaximal exercise in a similar demographic of recreationally active 
males. 
With dose and participant demographics similar across studies, the use of a 
randomised crossover design in Chapter 5 may provide a methodological insight as to 
why this study was the only one to report a beneficial effect of astaxanthin, even 
though a shorter supplementation period was undertaken. In previous research, for 
example, the markers of muscle damage and substrate utilisation obtained were 
reported to vary considerably, even between individuals of a similar fitness  
demographic (Goedecke et al., 2000, Bloomer et al., 2005, Venables, Achten and 
Jeukendrup, 2005, Bowtell et al., 2011). A potential advantage of Chapter 5 was, 
therefore, the ability for each participant to act as their own control, minimising the 
potential impact subtle differences in participant characteristics and individual 
responses to astaxanthin could have upon the outcome variable (Cleophas and de 
Vogel, 1998, Burke and Peeling, 2018). As such, this may have increased the ability 




during exercise. Future research conducted in astaxanthin should, therefore, consider 
implementing a randomised crossover study design when aiming to detect subtle 
changes in exercise recovery, metabolism or performance as a result of astaxanthin 
supplementation. 
 
6.4. Pharmacokinetics of Astaxanthin Uptake 
Pharmacokinetic data is available from research that has quantified the uptake and 
elimination kinetics of acute astaxanthin supplementation in human plasma using 
high-performance liquid chromatography (Østerlie, Bjerkeng and Liaaen-Jensen, 
2000, Mercke Odeberg et al., 2003, Coral-Hinostroza et al., 2004, Rüfer et al., 2008). 
The uptake kinetics of chronic supplementation, however, has only been analysed in 
humans by Rüfer et al. (2008) during the investigation of 28 healthy males over a 4 
week period. Prior to study onset, astaxanthin concentrations were quantified as non-
detectable, following which two randomised groups (n = 14 each group) consumed 
either 250 g of wild or aquacultured salmon daily, to obtain ~ 1.25 
mgday−1 astaxanthin (5 µg astaxanthing−1 salmon flesh). Following 6 days of 
consumption, astaxanthin concentrations reached a plateau of 33.7 ± 16.2 
nmolL−1 (wild salmon) and 52.4 ± 16.2 nmolL−1 (aquacultured salmon), respectively, 
with concentrations reported to not significantly change for the remainder of the 4 
week protocol (Rüfer et al., 2008). 
It therefore appears that when the intake of astaxanthin is chronic, maximal 
concentrations can be achieved and maintained within the first week of intake, even 




from one study only, where astaxanthin was consumed as part of the diet, requiring a 
daily intake of 250 g salmon (Rüfer et al., 2008). Future research should, therefore, 
aim to clarify the bioavailability of astaxanthin from a variety of different sources, 
including supplementation, with information regarding the elimination kinetics also 
of importance to understand how the availability of astaxanthin may diminish in 
humans over time. In doing so, an optimal supplementation strategy for astaxanthin 
intake in exercise humans can be devised, increasing the potential ability for the 
successful integration of astaxanthin into sport nutrition practices in the future. 
A limitation of each study in this thesis is that the uptake of astaxanthin was not 
verified from pre- to post-supplementation. As such, the supplementation strategies 
implemented in this thesis were informed by previous astaxanthin literature (Rüfer et 
al., 2008, Earnest et al., 2011, Res et al., 2013). An interesting finding reported in this 
thesis, however, is that a beneficial effect of astaxanthin was only reported following 
a shorter 7 day supplementation, and not following prolonged intakes of 4 weeks or 8 
weeks, respectively. As discussed in section 6.3 (Experimental Study Designs), this 
may simply be explained by 7 days of intake enabling the ability to conduct a 
randomised crossover design, minimising the potential impact subtle differences in 
participant characteristics and individual responses to astaxanthin could have upon the 
outcome variable. Without the uptake of astaxanthin being quantified, however, it is 
difficult to make a robust conclusion regarding the effect of astaxanthin on the 
outcome variables measured in this thesis. For example, it is uncertain as to whether 
the ergogenic effect reported in Chapter 5 was because astaxanthin was adequately 
taken up into the muscle. Similarly, it is uncertain as to whether the no effects reported 




up into the exercising muscle. Although compliance was ensured via daily text 
message reminders and a pill count post-ingestion, future study should seek to confirm 
this uptake in the plasma/serum or the muscle of its participants. 
A further limitation of each study in this thesis is that chronic dietary intake was not 
controlled or quantified beyond the 24 h period that preceded each experimental trial. 
Previously, the influence of 4-day dietary intake has been demonstrated to account for 
3.2% of the variation in MFO, with carbohydrate and fat intakes contributing either 
negatively or positively to MFO, respectively (Fletcher et al., 2017). With astaxanthin 
uptake significantly enhanced if consumed alongside dietary fats (Mercke Odeberg et 
al., 2003, Okada, Ishikura and Maoka, 2009), it is plausible to suggest that the chronic 
dietary intake of each participant recruited in the current thesis may have impacted the 
uptake and potential efficacy of astaxanthin on each outcome variable reported. As 
such, chronic dietary intake should be considered as a potential confounding variable 
that requires greater control during future practice within this research area. 
 
6.5. Practical Implications and Conclusion 
The outcomes reported in this thesis offer an interesting insight into the potential 
application of astaxanthin supplementation in exercising humans. Based on the data 
presented in Chapter 3 and Chapter 4 recommendations for the long-term 
supplementation of 4 mgday−1 or 12 mgday−1 astaxanthin for purposes of attenuating 
the muscle damage response to exercise or enhancing the fat oxidative capacity during 
submaximal exercise are seemingly unjustified in recreationally active males. The lack 




strategy utilised in both Chapter 3 and Chapter 4, with an ergogenic benefit of 
astaxanthin elicited in Chapter 5 following a shorter duration supplementation period. 
Indeed, the findings of Chapter 5 suggest that supplementation with 12 mgday−1 
astaxanthin for 7 days can improve performance and promote fat oxidation during 
endurance-type performance events. To enable the successful integration of 
astaxanthin supplementation in sport nutrition future investigations should aim to 
develop an optimal supplementation strategy for astaxanthin intake based upon human 
pharmacokinetic data. With this knowledge, further explorations into the efficacy of 
astaxanthin supplementation in exercising humans can be made while using a 
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